

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Expectation focused and frequency enhanced cognitive behavioral therapy for patients with major depression (EFFECT): A study protocol of a randomized active-control trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-065946
Article Type:	Protocol
Date Submitted by the Author:	23-Jun-2022
Complete List of Authors:	Ewen, Anne-Catherine; Philipps-University Marburg Faculty of Psychology, FB04 Clinical Psychology and Psychotherapy Bleichhardt, Gaby; Philipps-Universität Marburg, Clinical Psychology and Psychotherapy Rief, Winfried; Philipps University, Von Blanckenburg, Pia; Philipps-Universität Marburg, Clinical Psychology and Psychotherapy Wambach, Katrin; Philipps-Universität Marburg, Clinical psychology and psychotherapy Wilhelm, Marcel; Philipps-Universität Marburg,
Keywords:	Depression & mood disorders < PSYCHIATRY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, MENTAL HEALTH, PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts

1  
2  
3 **Expectation focused and frequency enhanced cognitive behavioral therapy for patients**  
4 **with major depression (EFFECT): A study protocol of a randomized active-control trial**  
5  
6  
7  
8  
9

10 Ewen, A. <sup>a</sup>, Bleichhardt, G. <sup>a</sup>, Rief, W. <sup>a</sup>, von Blanckenburg, P. <sup>a</sup>, Wambach, K. <sup>a</sup> & Wilhelm,  
11  
12 M. <sup>a</sup>  
13

14 <sup>a</sup> Philipps-University of Marburg, Germany, Department clinical psychology and  
15  
16  
17 psychotherapy  
18  
19  
20

21 **Author information:**  
22

23 Corresponding author: Anne-Catherine Ewen, M. Sc.  
24

25  
26 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
27  
28 Gutenbergstraße 18, 35032 Marburg, Germany  
29

30 E-Mail: [ewen@uni-marburg.de](mailto:ewen@uni-marburg.de)  
31

32 Dr. Gaby Bleichhardt  
33

34  
35 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
36  
37 Gutenbergstraße 18, 35032 Marburg, Germany  
38

39 E-Mail: [gaby.bleichhardt@staff.uni-marburg.de](mailto:gaby.bleichhardt@staff.uni-marburg.de)  
40

41 Prof. Dr. Winfried Rief  
42

43  
44 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
45  
46 Gutenbergstraße 18, 35032 Marburg, Germany  
47

48 E-Mail: [rief@staff.uni-marburg.de](mailto:rief@staff.uni-marburg.de)  
49

50 Dr. Pia von Blanckenburg  
51

52  
53 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
54  
55 Gutenbergstraße 18, 35032 Marburg, Germany  
56

57 E-Mail: [blanckep@staff.uni-marburg.de](mailto:blanckep@staff.uni-marburg.de)  
58

59 Dr. Katrin Wambach  
60

1  
2  
3 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
4  
5 Gutenbergstraße 18, 35032 Marburg, Germany  
6

7  
8 E-Mail: [wambach@staff.uni-marburg.de](mailto:wambach@staff.uni-marburg.de)  
9

10  
11 Dr. Marcel Wilhelm

12  
13 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
14  
15 Gutenbergstraße 18, 35037 Marburg, Germany  
16

17  
18 E-Mail: [marcel.wilhem@staff.uni-marburg.de](mailto:marcel.wilhem@staff.uni-marburg.de)  
19  
20

21  
22 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the  
23  
24 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive  
25  
26 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has  
27  
28 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for  
29  
30 US Federal Government officers or employees acting as part of their official duties; on a  
31  
32 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”)  
33  
34 its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the  
35  
36 Journal, to publish the Work in BMJ Open and any other BMJ products and to exploit all  
37  
38 rights, as set out in our licence.  
39  
40  
41  
42  
43  
44

#### 45 46 47 **Abstract**

48  
49 **Introduction.** The effectiveness of psychotherapy in depression is subject of an  
50  
51 ongoing debate. The mechanisms of change are still underexplored. Research tries to find  
52  
53 influencing factors fostering the effect of psychotherapy. In that context, the dose-response  
54  
55 relationship should receive more attention. Increasing the frequency of one to two sessions  
56  
57 per week seems to be a promising start. Moreover, the concept of expectations and its  
58  
59 influence in depression can be another auspicious approach. Dysfunctional expectations and  
60  
61 the lack of their modification are central in symptom maintenance. Expectation focused

1  
2  
3 psychological interventions (EFPI) have been investigated, primarily in the field of  
4  
5 depression. The aim of this study is to compare cognitive behavioral therapy (CBT) once a  
6  
7 week with a more intensified version of CBT (twice a week) in depression as well as to  
8  
9 include a third proof-of-principle intervention group receiving a condensed expectation  
10  
11 focused CBT.  
12  
13

14 **Methods and Analysis.** Participants are recruited through an outpatient clinic in  
15  
16 Germany. A current major depressive episode, diagnosed via structured clinical interviews  
17  
18 should present as the main diagnosis. The planned randomized-controlled trial will allow  
19  
20 comparisons between the following treatment conditions: CBT (1 session/week), condensed  
21  
22 CBT (2 sessions/week), and EFPI (2 sessions/week). All treatment arms include a total dose  
23  
24 of 24 sessions. Depression severity applies as the outcome variable (Beck Depression  
25  
26 Inventory II; BDI-II, Montgomery Asperg Depression Rating Scale; MADRS). A sample size  
27  
28 of n=150 is intended.  
29  
30  
31

32 **Ethics and dissemination.** The local ethics committee of the Department of Psychology,  
33  
34 Philipps-University Marburg approved the study (reference number 2020-68v). The final  
35  
36 research article including the study results is intended to be published in international peer-  
37  
38 reviewed journals.  
39  
40  
41  
42  
43  
44

45 **Key words.** cognitive behavioral therapy (CBT), once vs. twice weekly sessions,  
46  
47 expectation focused psychological interventions (EFPI), depression, psychotherapy research  
48

#### 49 **Strengths**

- 50  
51 • Naturalistic and practice-oriented randomized controlled design for testing the  
52  
53 effectiveness of psychotherapy
- 54  
55 • the article will provide first results concerning structural conditions allowing first  
56  
57 conclusions for possible implications  
58  
59  
60

- First study that includes expectation focused psychological interventions (EFPI) assuming dysfunctional expectations as main mechanisms of symptom persistence and the lack of change

### **Limitations**

- Depression as a highly comorbid disorder, manualized psychotherapy studies may limit the transfer to practice
- For economic reasons, it was opted against a 2 x 2 design, including only three treatment arms: CBT once weekly, CBT twice weekly, EFPI twice weekly

### **Theoretical background**

Major depression, as one form of mood disorders, is one of the most common mental disorders with a lifetime prevalence of 13 % in Europe [1]. In the last decades, research seemed to prove the effectiveness of different treatments in depression [2-5]. However, a meta-analysis reassessing the effects of psychotherapy for adult depression with the aim to control methodological biases in meta-analyses puts the effectiveness into question again [6, 7]. The need to find promising approaches to enhance effectiveness seems obvious. However, treatment research that focuses on theory-based factors might have reached its limits. A long line of research started to focus on common or unspecific factors leading to treatment success. Typical common factors are therapeutic relationship or alliance, treatment expectations, empathy and congruence [8, 9]. Especially the concept of expectations gets more and more attention as an important factor in psychopathology [10].

Furthermore, the consideration of common structural variables was rather neglected. It not only seems important to consider these factors to augment positive treatment outcome, but also for defining an evidence-based professional policy of psychotherapy in healthcare systems. Even in Germany, as one of the few European countries where psychotherapy is paid by health insurance, a length of twelve to sixty one-weekly 50-minute session for cognitive

1  
2  
3 behavioral therapy is the default [11]. With exception of the duration, the frequency of  
4  
5 sessions per week seems to be rather randomly determined due to convenience and a lack of  
6  
7 evidence.  
8  
9

10 In the last years psychotherapy researchers started investigating the dose-response  
11  
12 relationship [12-14]. As “dose”, different factors can be considered, e.g., total number of  
13  
14 sessions, number of sessions per week, or the session duration. Howard and colleagues [15]  
15  
16 were one of the first to look at the number of sessions needed to reach symptom recovery by  
17  
18 calculating a probit model (dose-response model). After eight sessions, 50% of the patients  
19  
20 showed symptom improvement, whereas 75% of the patients improved after 26 sessions.  
21  
22 Further evidence confirms the need of approximately 20 sessions to expect a symptom  
23  
24 recovery by over the half to two-thirds of the patients [13, 14, 16, 17]. The change pattern  
25  
26 seems to be negatively accelerated, as a greater effect per session occurs in earlier sessions,  
27  
28 which then decreases in the later sessions [18-20].  
29  
30  
31  
32

33 A meta regression analysis showed no significant influence of the duration of the  
34  
35 therapy, while replacing one session per week by two sessions per week increased the effect  
36  
37 by a small to medium effect size [21]. These findings could be supported by an RCT  
38  
39 comparing one versus two sessions per week, concluding that twice weekly sessions in  
40  
41 clinical practice could improve treatment outcome in depression [12]. A higher session  
42  
43 frequency seems to result in a faster recovery, making it a promising variable to improve the  
44  
45 efficiency of psychotherapy [22].  
46  
47  
48

49 Only very few studies dealt with the comparison of intensive and standard treatment  
50  
51 regarding the duration of one therapy session. Especially for anxiety disorders, indicating  
52  
53 mixed results about the superiority of intensive treatment forms, especially in long term [23-  
54  
55 25]. In conclusion, it seems more promising to increase the frequency (i.e., two single  
56  
57 sessions weekly) of psychotherapy instead of planning double length sessions.  
58  
59  
60

1  
2  
3 As mentioned above, the concept of expectation and its role in psychopathology  
4 should be better considered. The concept of expectations in psychological research leads back  
5 to action and decision making theories [26-28]. A consistent definition is still lacking [29].  
6  
7 Humans learn through a constant prediction updating based on external input [30-32].  
8  
9 Experiences lead to the development of specific expectations towards future events and  
10 proper behavior [33, 34]. However, expectations are not only unidirectionally formed by the  
11 external input through experiences. They also influence beforehand the experience in future  
12 situations, as it is well-observed in the so-called placebo effects [35-37]. Thus, expectations  
13 play a central role in psychotherapy, regarding the therapy outcome [38, 39] or the therapeutic  
14 relationship [40, 41].

15  
16 According to the underlying theoretical models [42, 43], the lack of expectation  
17 adaptation after expectation violating information is defined as fundamental. This is mainly  
18 explained through two mechanisms: the minimization of the importance of expectation-  
19 disconfirming evidence and the search for or the production of future expectation-confirming  
20 evidence [44]. Based on the ViolEx-model [10, 42], the process of cognitive immunization,  
21 i.e., the reappraisal of disconfirming information in order to maintain prior expectations, is  
22 demonstrated in first experimental designs, especially in people with depressive symptoms  
23 [45-47]. Depressed patients show increased dysfunctional expectations and at the same time a  
24 lack in the ability to accommodate these dysfunctional expectations after new expectation-  
25 disconfirming experiences [43, 48]. This was already described in the context of learned  
26 helplessness as a fundamental explanatory model of depression [49]. Different processes seem  
27 to inhibit expectation adaptation by expectation-inconsistent experiences, leading to rigid  
28 expectations and thinking [50].

29  
30 Integrating expectation focused psychological interventions (EFPI) into psychotherapy  
31 to directly address immunization processes is the next logical step [51, 52]. Based on the  
32 presented theoretical background, mechanisms that lead to rigid thought patterns (e.g.,  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 immunization or avoidance processes) can be made salient. This entails the possibility to  
4 integrate new (positive) experiences in future expectations. Kolb and colleagues [53]  
5  
6 emphasize that individuals should make new experiences to learn. It therefore seems crucial  
7  
8 to support patients in making new experiences and to facilitate learning processes that  
9  
10 challenge problem-specific expectations.  
11  
12  
13

14 As major depression is one of the most prevalent mental disorders, this study aims to  
15 find possible ways to foster psychotherapy by firstly specifying the necessary frequency for  
16 an effective psychotherapeutic treatment in depression and, secondly prove the effectiveness  
17 of expectation focused cognitive behavioral therapy in depression.  
18  
19  
20  
21  
22

23 For this study, three concrete hypotheses are formulated:

- 24 1. A standard CBT protocol leads to a higher reduction in depressive symptoms when applied  
25 twice weekly, compared to one session a week.  
26  
27
- 28 2. As a pilot, an innovative CBT program focusing and providing expectation-focused  
29 interventions (EFPI), also applied twice weekly, should lead to a significant reduction in  
30 depressive symptoms over time.  
31  
32  
33
- 34 3. The EFPI condition approaching expectations as core mechanisms with two sessions a  
35 week will show a superiority over the CBT condition twice weekly.  
36  
37  
38  
39  
40  
41

## 42 **Methods**

43  
44 The local ethics committee of the Department of Psychology, Philipps-University  
45 Marburg approved the study (reference number 2020-68v), which was pre-registered under  
46 drks.de (German Clinical Trials Register DRKS00023203).  
47  
48  
49  
50

### 51 **Patient and Public involvement**

52 Patients were primarily involved in the preparation of the study manuals (especially  
53 EFPI). Patients in treatment due to depression were giving input and feedback about the  
54 different interventions chosen and / or developed by the study investigators. We intend to  
55 provide the main results of the study to interested participants.  
56  
57  
58  
59  
60

## Population

Participants will mainly be recruited at the psychotherapy outpatient clinic (Psychotherapie Ambulanz Marburg; PAM) of the Philipps-University Marburg. If a current major depression episode is suspected in the initial interview, the patient will be informed about this study. The following inclusion criteria should be met: participants should be at least 18 years, have a sufficient knowledge of German, have a major depression episode according to DSM-IV as the main diagnosis and should fulfill a total BDI-II score over 13 (mild depression). Patients were excluded if they have had a psychotic disorder (now or in the past) or are addicted to substances such as alcohol, drugs, medication. Moreover, if psychopharmacological drugs are prescribed, the intake dose must be stable over the last 4 weeks and not be changed during the treatment and first follow-up phase. In accordance to Bruijniks and colleagues [12], a total sample size of 150 participants is planned (with a supposed small effect size of 0.25 and a alpha of 0.05, a power of 0.92 can be reached with a sample size of 150 by considering repeated measures, within-between interaction).

## Study Design and procedure

Patients who are interested in study participation undergo a short telephone interview on the inclusion criteria and are then invited to a diagnostic appointment. The inclusion and exclusion criteria are then thoroughly checked. If the inclusion criteria are met, the study procedure is explained, and an informed consent (see Appendix A1) form is signed. The patients are randomly assigned by one study leader following simple randomization (computerized random numbers) to one of the three groups and assigned to a study therapist. A coding list is maintained by one of the study leader during the ongoing study and is going to be deleted after study completion. The first six sessions are used as a run-in phase for assessments and establishing a therapeutic relationship, as well as the collection of further questionnaires and clinical history to confirm the diagnosis. The run-in phase is six weeks, frequency and content are independent of the treatment condition. Subsequently, the twenty-

1  
2  
3 four therapy sessions start. Depending on the treatment condition, one respectively two  
4  
5 therapy sessions take place per week. For those having appointments twice a week, the last  
6  
7 four therapy sessions are spread over 10 weeks (see figure 1). Moreover, a diagnostic  
8  
9 interview is conducted after the twentieth and twenty-fourth session. After the end of twenty-  
10  
11 four sessions, a first follow-up diagnostic interview takes place after three months of the last  
12  
13 (24<sup>th</sup>) session. In that time, no therapeutic sessions are allowed, and antidepressant medication  
14  
15 should be kept stable. Afterwards, further sessions can be conducted if necessary (e.g., for the  
16  
17 treatment of secondary diagnosis or uncovered symptoms). A second follow-up diagnostic  
18  
19 interview is planned two years after the end of study treatment (see figure 2).  
20  
21  
22

### 23 **Diagnostic assessments**

24  
25  
26 Psychotherapists in post gradual training conduct the diagnostic interviews and are  
27  
28 blinded to the condition. In the case of unblinding, the following diagnostic assessments will  
29  
30 be conducted by another, still blinded, diagnostician. The diagnostic interviews are supervised  
31  
32 by licensed therapists and supervisors. The first diagnostic interview consists of the study  
33  
34 information, the informed consent, the implementation of the German version of the structural  
35  
36 clinical interview for DSM-IV [54], and the BDI-II [55] by the client and the MADRS [56] by  
37  
38 the diagnostician. In the following diagnostic interviews, only the major depression section of  
39  
40 the SCID-IV is conducted to rate the MADRS. These external assessments by the  
41  
42 diagnosticians take place at baseline, after the twentieth and twenty-fourth therapy session, as  
43  
44 well as after three month and two years after therapy completion. All self-rating  
45  
46 questionnaires are answered after the sessions on a tablet using SoScisurvey [57].  
47  
48  
49  
50

### 51 **Type of Treatments**

52  
53 All therapists conducting the study therapy are psychotherapists in training and receive  
54  
55 regular supervision (after every fourth therapy session). The first cohort of study therapists  
56  
57 receives a workshop on the different treatment conditions and the study flow. The workshop  
58  
59  
60

1  
2  
3 is recorded to easily train new study therapists when needed. All therapists will be trained to  
4  
5 do both kind of treatments.  
6

7  
8 In all, the study includes three treatment samples. First, the treatment-as-usual (TAU)  
9  
10 group consists of one CBT session per week (TAU CBT). The second group receives a more  
11  
12 condensed CBT version with two CBT sessions per week during the main parts of treatment  
13  
14 (CBT condensed). The third group also receives two sessions per week, but the CBT approach  
15  
16 is based on expectation focused psychological interventions (EFPI condensed). For the second  
17  
18 and third condition, the last four sessions are spread over 10 weeks. After twenty-four  
19  
20 sessions, the treatment according to study protocol is completed. As mentioned above,  
21  
22 continuation of therapy, is possible after the 3-months follow up if necessary. After two  
23  
24 years, a second follow-up measurement will take place to estimate long-term therapy  
25  
26 effectiveness.  
27  
28  
29

30  
31 **CBT manual.** The CBT manual includes a description of the attitude and behavior of  
32  
33 a CBT therapist [58]. The manual is modularized and enables personalization by a selection  
34  
35 of up to three out of seven possible, problem-specific CBT modules. The first session deals  
36  
37 with psychoeducation on depression. Typical symptoms are collected, and an individual case  
38  
39 concept is developed including cognitions, feelings, and behavior. The seven modules include  
40  
41 inactivity, cognitive work, relaxation, problem solving, emotion regulation, interpersonal  
42  
43 difficulties, and self-esteem. Every module starts with a psychoeducational part linking the  
44  
45 patient's own problems with the respective module. Further on, worksheets are presented,  
46  
47 which were designed according to suggestions of different CBT-manuals for depression [58-  
48  
49 60]. The manual closes in session 24 with relapse prevention.  
50  
51  
52

53  
54 **EFPI manual.** In the first six sessions, psychoeducation on the link between  
55  
56 expectations and depressive symptoms is delivered. Participants should acquire knowledge  
57  
58 about expectations as a specific form of thoughts and how expectations regulate human  
59  
60 behavior. The advantages (e.g., fast behavior planning) and disadvantages (e.g., reduces

1  
2  
3 flexibility) of forming expectations are elaborated. The negative consequences of very rigid  
4 expectations are discussed. Through self-observation, personal expectations should be made  
5 salient. Explicit expectations on the therapy are addressed. Further on, the link between the  
6 patient's biography and the origin of their expectations is drawn. An introduction to  
7 behavioral experiments as an important tool to test, break, and change dysfunctional  
8 expectations is introduced. Cognitive immunization, as a mechanism of reappraising new  
9 information to fit into prior expectations and to prevent expectation change despite  
10 contradicting experiences, is explained, and introduced based on the patient's personal  
11 examples.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24 After the psychoeducation phase, behavioral experiments are to be planned and  
25 conducted with the aim to test dysfunctional expectations considering the patient's  
26 immunization strategies. The manual gives examples on behavioral experiments for different  
27 depression specific problems (parallel to modules CBT manual). The therapists are supposed  
28 to be very flexible in planning behavioral experiments. It is obligatory to carry out at least one  
29 behavior experiment between (or within) each session. For relapse prevention, which is  
30 addressed in the 24<sup>th</sup> session, the prior expectations towards therapy are reviewed, learned  
31 strategies are collected, and future plans are elaborated.

### 42 **Assessments**

43  
44 The timepoints of the different assessments used are summarized in table 1.

45  
46  
47 **Demographic variables.** Different variables about the participants will be assessed  
48 including gender, age, nationality, mother language, education, and occupation.

49  
50  
51 **Primary outcome.** To analyze symptom reduction the self-rating scale Beck  
52 Depression Inventory II – German Version [55] is used, as well as the expert rating scale  
53 Montgomery Asperg Depression Rating Scale MADRS [56]. The MADRS is a ten-item  
54 questionnaire for clinicians to rate depressive symptoms on a seven-rating scale while the  
55 patient is interviewed by them. Again, a higher sum-score indicates a more severe depression.  
56  
57  
58  
59  
60

1  
2  
3 A sum score of 0 to 7 means no depression, 7 to 19 indicates a mild depression, 20 to 34  
4 moderate and a sum score over 34 is noted as severe depression.  
5  
6

7  
8 **Secondary outcome.** To assess the general symptom burden, the revised German  
9 version of the symptom checklist SCL-90 [61] is used. With ninety items, different symptoms  
10 are assessed that are grouped into following subscales: somatization, compulsivity,  
11 depression, insecurity in social contact, anxiety, aggression, phobia, paranoia, psychoticism.  
12 Dysfunctional expectations are assessed with the depressive expectations scale DES [48].  
13 Using 25 items, dysfunctional expectations about social rejection, social support, mood  
14 regulation, and ability to perform are assessed. The therapeutic alliance is assessed with the  
15 helping alliance questionnaire HAQ [62] integrating two eleven-item questionnaires, one for  
16 the patient and one for the clinician asking about the therapeutic relationship. To assess  
17 specific expectations towards the treatment, the six-item credibility/expectancy questionnaire  
18 CEQ [63] is used.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Overview of the study instruments and the survey timepoints.

Domain	Instrument	Inclusion diagnostic	Probatory (6 sessions)	T 10	T20	T24	FU 1 after 3 moths	FU 2 after 2 years
Demographic and amnesic information	demographics	x	x					
Depressive symptom severity	BDI-II	x	x	x	x	x	x	x
	MADRS	x			x	x	x	x
	SCID-IV	x						
General symptoms	SCL-90		x	x	x	x	x	
Therapeutic alliance	HAQ		x	x	x	x	x	
Expectations and immunization	CEQ		x	x	x	x	x	x
	DES		x	x	x	x	x	x
	IMS		x	x	x	x	x	x
Analogue scales about homework, engagement, actual impairment, actual expectation towards treatment, negative expectations	self-formulated items	x	x	x	x	x	x	x

**Note.** BDI-II Beck Depression Inventory, MADRS Montgomery Asperg Rating Scale, SCID-IV structural clinical interview for DSM-IV, SCL-90 Symptom Checklist, HAQ Helping Alliance Questionnaire, CEQ Credibility and Expectancy Questionnaire, DES Depressive Expectation Scale, IMS Immunization Scale; Analogue scales are assessed for every therapeutic session as momentary assessment

1  
2  
3  
4  
5 Moreover, to measure cognitive immunization the Immunization scale (IMS)  
6 including 23 items is used [64]. To test for acceptance, drop-out rates will be compared  
7 between the three conditions. Treatment adherence will be controlled by analyses of the  
8 recorded sessions by study independent raters.  
9  
10  
11  
12

### 13 14 **Every-session monitoring.**

15  
16 In every therapy session, patients are supposed to answer questions regarding  
17 homework completion, engagement (“From the last session to this one, my commitment to  
18 therapy was”: extreme low to extreme high 0-100), depressive symptoms [65], and own  
19 expectations [63] to monitor treatment progress. The questions were adapted by the authors  
20 for the progress diagnostics.  
21  
22  
23  
24  
25  
26

### 27 28 **Statistical Analysis**

29  
30 The complete anonymous dataset including all important subject data is regularly  
31 supplemented during the ongoing study (a.o., demographics, protocol violations, completed  
32 questionnaires). Intention-to-treat analyses are planned. At first, missing values and dropouts  
33 will be analyzed regarding their distribution. Due to clustered data, a certain estimated  
34 amount of missing data, as well as a time variable as a continuous variable, mixed models for  
35 repeated measures shall be calculated [66]. In accordance to the study of Bruijniks and  
36 colleagues [12], multilevel analyses will be calculated to analyze the frequency condition  
37 (once vs. twice weekly), as well as the intervention form (CBT vs. EFPI) on depressive  
38 symptoms (BDI-II scores and MADRS scores) over the treatment time first including the  
39 interaction terms time x frequency and time x treatment. To analyze if the frequency effect  
40 will differ between therapy forms, a second model with the interaction term time x frequency  
41 x intervention will be calculated. Significance levels will be set at  $p < 0.05$ . The same models  
42 will be used for secondary outcomes. Further on, effect sizes (Cohen’s  $d$ ) will be calculated.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Discussion**



1  
2  
3 This study will analyze the influence of session frequency, as well as the influence of  
4 specific expectations on psychotherapy effectiveness. Strengths and limitations are discussed  
5 in the following.  
6  
7  
8  
9

10 **Limitations.** To standardize the treatment groups, a CBT manual as well as an EFPI  
11 manual was written. Depression is known as a highly comorbid disorder [67, 68], the manual  
12 might not be flexible enough. To counteract the limitation, the CBT manual was modularized,  
13 so the therapists have the possibility to choose personalized modules. For the EFPI manual,  
14 only the psychoeducation sessions are completely predefined, whereas the chosen topics in  
15 therapy are mutually defined by patients and therapists. The only specification by the protocol  
16 is that at least one behavioral experiment must be conducted in / between every session. In  
17 that sense, the authors support the increasing idea of tailoring psychotherapy to the person  
18 [69]. As the EFPI treatment is still in its pilot phase as well as to avoid underpowered  
19 samples, we opted against a 2 x 2 design, and for the neglect of an EFPI once weekly  
20 condition.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 **Strengths.** This study has a well-structured randomized controlled design, whereas  
36 the execution of the study is very practice oriented and naturalistic. The study directly  
37 addresses the structure of care, allowing people with mental health problems to be helped  
38 quickly. The study therapists are all in their psychotherapist training, whereby differences in  
39 psychotherapeutic experience and other therapeutic differences are tried to be kept low, as it  
40 is done by the randomization. They are all supervised by CBT- or EFPI-supervisors.  
41 Moreover, the innovative expectation focused therapy manual can directly be compared to a  
42 well-established and evidence-based psychotherapy form. We will also evaluate one treatment  
43 arm focusing on the maintenance and change of problem-specific expectations. Such a focus  
44 promises powerful efficacy, because its close relation to brain functions, central treatment  
45 mechanisms, and mechanisms of change.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3       **Expected benefit.** Important implications on therapy session frequency can be drawn  
4  
5 to create optimal learning conditions. We address the practical execution of psychotherapy  
6  
7 and may suggest a certain guideline concerning the frequency of psychotherapy sessions per  
8  
9 week. If we confirm existing literature, psychotherapy should be implemented in a shorter  
10  
11 time with a two-sessions-per-week-dose. This would especially be a benefit in reducing  
12  
13 waiting time for psychotherapy. In Germany the waiting time amounted 2018 twenty weeks  
14  
15 [70], whereas during the COVID pandemic the time is estimated to increase constantly [71].  
16  
17

18  
19       Further on, this study will be the first one delivering information on the feasibility of  
20  
21 an expectation focused therapy manual in depression. Well-established questionnaires  
22  
23 measuring dysfunctional expectations as well as immunization are not available yet, whereas  
24  
25 first attempts to operationalize the concepts are already done [48]. Further research should  
26  
27 foster valid instruments assessing and validating the constructs of the ViolEx-model. The  
28  
29 EFPI intervention promises to be a theory-driven intervention, based on the ViolEx model  
30  
31 considering disorder-unspecific common factors, with a clear treatment focus that can result  
32  
33 in very powerful effects [72].  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Contributorship statement**  
6

7 **Anne-Catherine Ewen:** Conceptualization, Writing – Original draft, Project administration  
8

9  
10 **Gaby Bleichhardt:** Conceptualization, Writing – Review & Editing, therapist supervision  
11

12 **Winfried Rief:** Conceptualization, Supervision, Writing – Review & Editing **Pia von**  
13

14 **Blanckenburg:** Conceptualization, Writing – Review & Editing **Katrin Wambach:**  
15

16 Conceptualization, Writing – Review & Editing, therapist supervision **Marcel Wilhelm:**  
17

18 Conceptualization, Writing – Review & Editing, Supervision, Project administration  
19

20  
21 **Competing interests:** No conflict of interest to report.  
22

23  
24 **Funding:** This study is not funded.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Literature

1. Investigators, E.M., et al., *Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project*. Acta psychiatrica scandinavica, 2004. **109**: p. 21-27.
2. De Maat, S., et al., *Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis*. Psychotherapy Research, 2006. **16**(5): p. 566-578.
3. Ekers, D., D. Richards, and S. Gilbody, *A meta-analysis of randomized trials of behavioural treatment of depression*. Psychological Medicine, 2008. **38**(5): p. 611-623.
4. Gloaguen, V., et al., *A meta-analysis of the effects of cognitive therapy in depressed patients*. Journal of affective disorders, 1998. **49**(1): p. 59-72.
5. Arroll, B., et al., *Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis*. The Annals of Family Medicine, 2005. **3**(5): p. 449-456.
6. Cuijpers, P., et al., *Was Eysenck right after all? A reassessment of the effects of psychotherapy for adult depression*. Epidemiology and Psychiatric Sciences, 2019. **28**(1): p. 21-30.
7. Cuijpers, P., et al., *How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence*. World psychiatry, 2016. **15**(3): p. 245-258.
8. Wampold, B.E., *How important are the common factors in psychotherapy? An update*. World Psychiatry, 2015. **14**(3): p. 270-277.

- 1  
2  
3 9. Nahum, D., C.A. Alfonso, and E. Sönmez, *Common factors in psychotherapy*, in  
4  
5 *Advances in psychiatry*. 2019, Springer. p. 471-481.  
6
- 7  
8 10. Rief, W., et al., *Expectancies as core features of mental disorders*. Current opinion in  
9  
10 psychiatry, 2015. **28**(5): p. 378-385.  
11
- 12 11. Bundesausschuss, G., *Psychotherapie-Richtlinie*. 2009, Bundesanzeiger.  
13
- 14 12. Bruijniks, S.J.E., et al., *The effects of once- versus twice-weekly sessions on*  
15  
16 *psychotherapy outcomes in depressed patients*. The British Journal of  
17  
18 Psychiatry 2020: p. 1-9.  
19
- 20 13. Harnett, P., A. O'Donovan, and M.J. Lambert, *The dose response relationship in*  
21  
22 *psychotherapy: Implications for social policy*. Clinical Psychologist, 2010. **14**(2): p.  
23  
24 39-44.  
25
- 26 14. Hansen, N.B., M.J. Lambert, and E.M. Forman, *The psychotherapy dose-response*  
27  
28 *effect and its implications for treatment delivery services*. Clinical Psychology-Science  
29  
30 and Practice, 2002. **9**(3): p. 329-343.  
31
- 32 15. Howard, K.I., et al., *The dose-effect relationship in psychotherapy*. American  
33  
34 psychologist, 1986. **41**(2): p. 159.  
35
- 36 16. Anderson, E.M. and M.J. Lambert, *A survival analysis of clinically significant change*  
37  
38 *in outpatient psychotherapy*. Journal of Clinical Psychology, 2001. **57**(7): p. 875-888.  
39
- 40 17. Hansen, N.B. and M.J. Lambert, *An evaluation of the dose-response relationship in*  
41  
42 *naturalistic treatment settings using survival analysis*. Mental Health Services  
43  
44 Research, 2003. **5**(1): p. 1-12.  
45
- 46 18. Barkham, M., et al., *Dose-effect relations in time-limited psychotherapy for*  
47  
48 *depression*. Journal of consulting and clinical psychology, 1996. **64**(5): p. 927.  
49
- 50 19. Kopta, S.M., et al., *Patterns of symptomatic recovery in psychotherapy*. Journal of  
51  
52 consulting and clinical psychology, 1994. **62**(5): p. 1009.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 20. Robinson, L., J. Delgado, and S. Kellett, *The dose-response effect in routinely*  
4  
5 *delivered psychological therapies: A systematic review*. *Psychotherapy Research*,
- 6  
7 2020. **30**(1): p. 79-96.
- 8  
9  
10 21. Cuijpers, P., et al., *How much psychotherapy is needed to treat depression? A*  
11  
12 *metaregression analysis*. *Journal of Affective Disorders*, 2013. **149**(1-3): p. 1-13.
- 13  
14 22. Erekson, D.M., M.J. Lambert, and D.L. Eggett, *The Relationship Between Session*  
15  
16 *Frequency and Psychotherapy Outcome in a Naturalistic Setting*. *Journal of*
- 17  
18 *Consulting and Clinical Psychology*, 2015. **83**(6): p. 1097-1107.
- 19  
20 23. Abramowitz, J.S., E.B. Foa, and M.E. Franklin, *Exposure and ritual prevention for*  
21  
22 *obsessive-compulsive disorder: Effects of intensive versus twice-weekly sessions*.
- 23  
24 *Journal of Consulting and Clinical Psychology*, 2003. **71**(2): p. 394-398.
- 25  
26 24. Herbert, J.D., et al., *Standard versus extended cognitive behavior therapy for social*  
27  
28 *anxiety disorder: A randomized-controlled trial*. *Behavioural and Cognitive*
- 29  
30 *Psychotherapy*, 2004. **32**(2): p. 131-147.
- 31  
32 25. Bohni, M.K., et al., *A randomized study of massed three-week cognitive behavioural*  
33  
34 *therapy schedule for panic disorder*. *Acta Psychiatrica Scandinavica*, 2009. **120**(3): p.
- 35  
36 187-195.
- 37  
38 26. Atkinson, J.W. and N.T. Feather, *A theory of achievement motivation*. Vol. 66. 1966:  
39  
40 Wiley New York.
- 41  
42 27. Kahneman, D. and A. Tversky, *Prospect Theory of Decisions Under Risk*.
- 43  
44 *Econometrica*, 1979. **47**(2): p. 1156-67.
- 45  
46 28. Ajzen, I., *From intentions to actions: A theory of planned behavior*, in *Action control*.
- 47  
48 1985, Springer. p. 11-39.
- 49  
50 29. Laferton, J.A., et al., *Patients' expectations regarding medical treatment: a critical*  
51  
52 *review of concepts and their assessment*. *Frontiers in psychology*, 2017. **8**: p. 233.
- 53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30. Berg, M., M. Feldmann, and T. Kube, *Oversampled and undersolved: Depressive*  
4 *rumination from a predictive coding perspective*. 2021.  
5  
6  
7  
8 31. Smith, R., et al., *A Bayesian computational model reveals a failure to adapt*  
9 *interoceptive precision estimates across depression, anxiety, eating, and substance use*  
10 *disorders*. PLoS computational biology, 2020. **16**(12): p. e1008484.  
11  
12  
13  
14 32. Visalli, A., et al., *Bayesian modeling of temporal expectations in the human brain*.  
15 *Neuroimage*, 2019. **202**: p. 116097.  
16  
17  
18  
19 33. Bandura, A., *Self-efficacy: toward a unifying theory of behavioral change*.  
20 *Psychological review*, 1977. **84**(2): p. 191.  
21  
22  
23  
24 34. Lightsey, R., *Albert Bandura and the exercise of self-efficacy*. *Journal of Cognitive*  
25 *Psychotherapy*, 1999. **13**(2): p. 158.  
26  
27  
28  
29 35. Evers, A.W., et al., *Implications of placebo and nocebo effects for clinical practice:*  
30 *expert consensus*. *Psychotherapy and psychosomatics*, 2018. **87**(4): p. 204-210.  
31  
32  
33 36. Kirsch, I., *Response expectancy theory and application: A decennial review*. *Applied*  
34 *and preventive Psychology*, 1997. **6**(2): p. 69-79.  
35  
36  
37  
38 37. Bingel, U., *Placebo 2.0: the impact of expectations on analgesic treatment outcome*.  
39 *Pain*, 2020. **161**: p. S48-S56.  
40  
41  
42  
43 38. Greenberg, R.P., M.J. Constantino, and N. Bruce, *Are patient expectations still*  
44 *relevant for psychotherapy process and outcome?* *Clinical psychology review*, 2006.  
45 **26**(6): p. 657-678.  
46  
47  
48  
49 39. Constantino, M.J., et al., *A meta-analysis of the association between patients' early*  
50 *treatment outcome expectation and their posttreatment outcomes*. *Psychotherapy*,  
51 2018. **55**(4): p. 473.  
52  
53  
54  
55  
56 40. Barber, J.P., et al., *The associations among improvement and alliance expectations,*  
57 *alliance during treatment, and treatment outcome for major depressive disorder*.  
58 *Psychotherapy Research*, 2014. **24**(3): p. 257-268.  
59  
60

- 1  
2  
3 41. Patterson, C.L., B. Uhlin, and T. Anderson, *Clients' pretreatment counseling*  
4  
5 *expectations as predictors of the working alliance*. Journal of Counseling Psychology,  
6  
7 2008. **55**(4): p. 528.  
8  
9  
10 42. Gollwitzer, M., A. Thorwart, and K. Meissner, *Editorial: Psychological Responses to*  
11  
12 *Violations of Expectations*. Frontiers in Psychology, 2018. **8**: p. 3.  
13  
14 43. Rief, W. and J. Joormann, *Revisiting the cognitive model of depression: The role of*  
15  
16 *expectations*. Clinical Psychology in Europe, 2019. **1**: p. 1-19.  
17  
18  
19 44. Pinguart, M., et al., *Why expectations do or do not change after expectation violation:*  
20  
21 *A comparison of seven models*. Consciousness and Cognition, 2021. **89**: p. 103086.  
22  
23  
24 45. Kube, T., et al., *Why dysfunctional expectations in depression persist - Results from*  
25  
26 *two experimental studies investigating cognitive immunization*. Psychological  
27  
28 *Medicine*, 2019. **49**(9): p. 1532-1544.  
29  
30  
31 46. Kube, T., W. Rief, and J.A. Glombiewski, *On the Maintenance of Expectations in*  
32  
33 *Major Depression - Investigating a Neglected Phenomenon*. Frontiers in Psychology,  
34  
35 2017. **8**.  
36  
37  
38 47. Kube, T., et al., *How to modify persisting negative expectations in major depression?*  
39  
40 *An experimental study comparing three strategies to inhibit cognitive immunization*  
41  
42 *against novel positive experiences*. Journal of Affective Disorders, 2019. **250**: p. 231-  
43  
44 240.  
45  
46  
47 48. Kube, T., et al., *Focusing on situation-specific expectations in major depression as*  
48  
49 *basis for behavioural experiments - Development of the Depressive Expectations*  
50  
51 *Scale*. Psychology and Psychotherapy-Theory Research and Practice, 2017. **90**(3): p.  
52  
53 336-352.  
54  
55  
56 49. Abramson, L.Y., M.E. Seligman, and J.D. Teasdale, *Learned helplessness in humans:*  
57  
58 *critique and reformulation*. Journal of abnormal psychology, 1978. **87**(1): p. 49.  
59  
60



- 1  
2  
3 50. Liknaitzky, P., L.D. Smillie, and N.B. Allen, *Out-of-the-Blue: Depressive Symptoms*  
4 *are Associated with Deficits in Processing Inferential Expectancy-Violations Using a*  
5 *Novel Cognitive Rigidity Task*. *Cognitive Therapy and Research*, 2017. **41**(5): p. 757-  
6 776.  
7  
8  
9  
10  
11  
12 51. Kube, T., J.A. Glombiewski, and W. Rief, *Expectation-Focused Psychotherapeutic*  
13 *Interventions for People with Depressive Symptoms*. *Verhaltenstherapie*, 2019. **29**(4):  
14 p. 281-291.  
15  
16  
17  
18 52. Rief, W. and J.A. Glombiewski, *Expectation-Focused Psychological Interventions*  
19 *(EFPI)*. *Verhaltenstherapie*, 2016. **26**(1): p. 47-54.  
20  
21  
22  
23 53. Kolb, D.A., R.E. Boyatzis, and C. Mainemelis, *Experiential learning theory: Previous*  
24 *research and new directions*, in *Perspectives on thinking, learning, and cognitive*  
25 *styles*. 2014, Routledge. p. 227-248.  
26  
27  
28  
29  
30 54. Wittchen, H.U., et al., *SKID. Strukturiertes klinisches Inter-view für DSM-IV, Achse I,*  
31 *deutsche Version 1997*, Göttingen: Hogrefe.  
32  
33  
34 55. Hautzinger, M., F. Keller, and C. Kühner, *BDI II. Beck-Depressions-Inventar*. Vol. 2.  
35 *Auflage*. 2009, London: Pearson.  
36  
37  
38  
39 56. Schmidtke, A., et al., *Studies of the reliability and validity of the German version of*  
40 *the Montgomery-Asberg Depression Rating Scale (MADRS)*. *Schweizer Archiv für*  
41 *Neurologie und Psychiatrie (Zurich, Switzerland: 1985)*, 1988. **139**(2): p. 51-65.  
42  
43  
44  
45 57. Leiner, D.J., *SoSci Survey (Version 3.1.06) [Computer software]*. 2019.  
46  
47  
48 58. Hautzinger, M., *Kognitive Verhaltenstherapie bei Depressionen*. 2013, Weinheim:  
49 Beltz Verlag.  
50  
51  
52  
53 59. Faßbinder, E., et al., *Therapie-Tools Depression: Mit E-Book inside und*  
54 *Arbeitsmaterial*. 2015: Beltz.  
55  
56  
57  
58 60. Schaub, A., E. Roth, and U. Goldmann, *Kognitiv-psychoedukative therapie zur*  
59 *bewältigung von depressionen: Ein therapiemanual*. Vol. 39. 2013: Hogrefe Verlag.  
60

- 1  
2  
3 61. Schmitz, N., et al., *The symptom check-list-90-R (SCL-90-R): a German validation*  
4 *study*. Quality of Life Research, 2000. **9**(2): p. 185-193.  
5  
6  
7  
8 62. Bassler, M., B. Potratz, and H. Krauthauser, *Der "Helping Alliance Questionnaire"*  
9 *(HAQ) von Luborsky*. Psychotherapeut, 1995. **40**: p. 23-32.  
10  
11  
12 63. Devilly, G.J. and T.D. Borkovec, *Psychometric properties of the*  
13 *credibility/expectancy questionnaire*. Journal of Behavior Therapy and Experimental  
14 *Psychiatry*, 2000. **31**(2): p. 73-86.  
15  
16  
17  
18  
19 64. Ewen, A., W. Rief, and M. Wilhelm, *Immunization Scale*. 2021.  
20  
21 65. Gräfe, K., et al., *Screening psychischer Störungen mit dem "Gesundheitsfragebogen*  
22 *für Patienten (PHQ-D)"*. Diagnostica, 2004. **50**(4): p. 171-181.  
23  
24  
25  
26 66. Krueger, C. and L. Tian, *A comparison of the general linear mixed model and*  
27 *repeated measures ANOVA using a dataset with multiple missing data points*.  
28 *Biological research for nursing*, 2004. **6**(2): p. 151-157.  
29  
30  
31  
32  
33 67. Kessler, R.C., et al., *Prevalence, severity, and comorbidity of 12-month DSM-IV*  
34 *disorders in the National Comorbidity Survey Replication*. Archives of general  
35 *psychiatry*, 2005. **62**(6): p. 617-627.  
36  
37  
38  
39  
40 68. Goldberg, D. and J. Fawcett, *The importance of anxiety in both major depression and*  
41 *bipolar disorder*. Depression and anxiety, 2012. **29**(6): p. 471-478.  
42  
43  
44 69. Norcross, J.C. and B.E. Wampold, *What works for whom: Tailoring psychotherapy to*  
45 *the person*. Journal of clinical psychology, 2011. **67**(2): p. 127-132.  
46  
47  
48  
49 70. Bundespsychotherapeutenkammer, B. *Ein Jahr nach der Reform der*  
50 *Psychotherapie-Richtlinie – Wartezeiten 2018*. 2018; Available from:  
51 [https://www.bptk.de/wp-](https://www.bptk.de/wp-content/uploads/2019/01/20180411_bptk_studie_wartezeiten_2018.pdf)  
52 [content/uploads/2019/01/20180411\\_bptk\\_studie\\_wartezeiten\\_2018.pdf](https://www.bptk.de/wp-content/uploads/2019/01/20180411_bptk_studie_wartezeiten_2018.pdf).  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 71. Brakemeier, E.-L., et al., *Die COVID-19-Pandemie als Herausforderung für die*  
4 *psychische Gesundheit. Zeitschrift für Klinische Psychologie und Psychotherapie,*  
5 *2020.*  
6  
7  
8  
9  
10 72. Rief, W., et al., *Preoperative optimization of patient expectations improves long-term*  
11 *outcome in heart surgery patients: results of the randomized controlled PSY-HEART*  
12 *trial. BMC medicine, 2017. 15(1): p. 1-13.*  
13  
14  
15  
16  
17  
18

## 19 **Figures**

### 20 Figure 1. *Study Procedure.*

21  
22  
23 *Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused  
24 psychotherapeutic intervention  
25

### 26 Figure 2. *Study Design*


27  
28  
29 *Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused  
30 psychotherapeutic treatment, T measurement timepoint, FU Follow-up  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Figure 1. *Study Procedure.*



*Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic intervention

Figure 2. Study Design  
randomization



*Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic treatment, T measurement timepoint, FU Follow-up

## Appendix

### A 1.

Study information and informed consent (Original in German)

## „Expectation Focused and Frequency Enhanced Cognitive-behavioral Therapy (EFFECT)“

### Informationsschreiben für Studienteilnehmerinnen und Studienteilnehmer

Liebe Studieninteressierte, Lieber Studieninteressierter,

wir freuen uns über Ihr Interesse an unserem Forschungsprojekt EFFECT, in dem wir einerseits kognitiv-verhaltenstherapeutische Behandlungen mit einmal wöchentlichen und zweimal wöchentlichen Therapiesitzungen vergleichen wollen und andererseits die Wirksamkeit von zwei kognitiv-verhaltenstherapeutischen Behandlungsmethoden vergleichen.

Das Therapieangebot ist Mittelpunkt eines Forschungsprojekts (Leitung: Prof. Dr. Winfried Rief, Professur für klinische Psychologie und Psychotherapie, Philipps-Universität Marburg).

### Worum geht es in dieser Studie?

Wir wissen aus verschiedenen Studien, dass Psychotherapie bei psychischen Erkrankungen wie Depressionen wirksam ist und zu einer Reduktion der depressiven Symptome führt. Wir wissen aber auch, dass es viele Faktoren gibt, die einen Einfluss auf den Erfolg der Behandlung haben können. Dazu gehört einerseits die Anzahl der Therapie-Sitzungen pro Woche. In dieser Studie wollen wir untersuchen, ob die Anzahl der Therapie-Sitzungen pro Woche (1 vs. 2) die Wirksamkeit der kognitiven Verhaltenstherapie zur Behandlung von Depressionen verbessern kann.

Weiterhin wissen wir aus der Forschung, dass Erwartungen unser Verhalten und unser Befinden beeinflussen können und sogar einen Einfluss auf den Therapie-Erfolg haben können. Deswegen geht es in dieser Studie auch darum neue und innovative erwartungsfokussierte Therapietechniken im Rahmen einer kognitiven Verhaltenstherapie zu untersuchen.

### Was ist kognitive Verhaltenstherapie (KVT) genau?

Die kognitive Verhaltenstherapie ist eine Form der Psychotherapie, welche sich vorrangig auf das Hier und Jetzt bezieht. Weiter geht die KVT davon aus, dass das Verhalten, die Gedanken und die Gefühle eng zusammenhängen, wobei die aktive Veränderung des Verhaltens und den Gedanken, die Gefühle dauerhaft verändern kann. Das Verhalten das ein Mensch zeigt, ist meist ein Ergebnis von bewussten und nichtbewussten Lernprozessen. Im Rahmen der Psychotherapie wird das Verhalten gemeinsam analysiert, um es später bewusst zu ändern. Kognitionen beziehen sich auf unser Denken. Dabei wird geschaut, welche Gedanken zur psychischen Störung beitragen, um diese mit verschiedenen Techniken zu ändern oder zu ersetzen. Weiter werden eigene Stärken und Fähigkeiten benutzt, um diesen Veränderungsprozess zu unterstützen.

### Was ist der Nutzen?

Mit Ihrer Teilnahme leisten Sie einen wichtigen Beitrag für die Wissenschaft und erlauben uns einerseits depressive Störungen und andererseits die Wirkungsweisen von psychotherapeutischen Behandlungen

besser zu verstehen, um weiterhin die Behandlungsmöglichkeiten stetig anpassen und verbessern zu können.

### **Wer kann an dieser Studie teilnehmen?**

Alle Personen über 18 Jahren können sich für die Studie anmelden. Gute Deutschkenntnisse werden vorausgesetzt. Nach der Durchführung eines Interviews und dem Ausfüllen der Fragebögen wird überprüft, ob alle Kriterien für den Einschluss in die Studie erfüllt sind. Dies wird mit Ihnen in einem Rückmeldegespräch besprochen und das weitere Vorgehen wird geplant. In diesem Gespräch werden Sie dann auch Rückmeldung über die Diagnostik bekommen.

### **Wie sieht der Ablauf der Studie aus?**

Nach dem ersten Anmeldegespräch in der Ambulanz und nach Ihrer Entscheidung, an der Studie teilnehmen zu wollen, werden Sie zufällig einer von drei Behandlungsbedingungen und einem/einer Therapeuten/Therapeutin zugeteilt. Danach folgen 7 Sitzungen, welche zur ausführlichen Diagnostik dienen (je nach Bedingung zweimal wöchentlich oder einmal wöchentlich). In diesen 7 Sitzungen wird der/die Therapeut/ Therapeutin mithilfe von Fragebögen und Interviews eine Diagnose nach den Kriterien der internationalen Diagnostiksysteme (ICD-10 und DSM-IV) stellen und einen Antrag an die Krankenkasse für die Kostenübernahme der Psychotherapie stellen.

Nach diesen 7 Sitzungen beginnt die Behandlung. Diese beträgt dann 24 Therapie-Sitzungen. Je nach Zufallszuteilung werden die Sitzungen zweimal pro Woche oder einmal pro Woche stattfinden. Damit wir die Erfolge der Therapie beurteilen können, werden Sie verschiedene Fragebögen zu verschiedenen Zeitpunkten ausfüllen. Diese Fragebögen beziehen sich vor allem auf Ihre aktuellen Belastungen, Ihre Stimmung, Ihre Erwartungen und Ihre subjektive Beurteilung des Therapie-Erfolges und der Beziehung zum/zur Therapeuten/ Therapeutin. Die Messzeitpunkte, bei denen Sie diese Fragebögen ausfüllen, werden einmal am Anfang der Therapie, einmal in der 10. Therapiewoche, nach der 20., nach der 24. Therapiewoche und nach 3 Monaten nach dem Therapie-Ende, sowie nach 2 Jahren stattfinden.

### **Wie wird man der Art und Form der Behandlung zugeordnet?**

Die Therapieformen (KVT und KVT mit erwartungsfokussierten Interventionen (EFPI); Sitzungen 1 vs. 2 mal pro Woche) entsprechen dem neuesten Stand der Wissenschaft. Alle Behandlungen werden von speziell ausgebildeten Therapeutinnen und Therapeuten durchgeführt. Die Zuordnung zu einer Bedingung erfolgt per Zufall, d.h. jeder Teilnehmer/ jede Teilnehmerin wird per Zufallsentscheidung und nicht aufgrund bestimmter Eigenschaften einer der drei Therapieformen zugeordnet.

### **Was sind mögliche Nebenwirkungen, Belastungen und Risiken?**

Bislang gibt es aus der Forschung nur sehr wenige Belege für Nebenwirkungen in der Psychotherapie. In der geplanten Studie sind keine negativen Effekte auf Sie zu erwarten. Die Therapie an sich kann anstrengend und ermüdend sein und kann manchmal negative Gefühle auslösen. Um diese negativen Effekte kontinuierlich erfassen zu können, wird der Therapeut/ die Therapeutin Sie in jeder Stunde nach Ihrem aktuellen Befinden fragen, um mögliche negative Gefühle aufgreifen und bearbeiten zu können. Alle Therapeutinnen und Therapeuten stehen unter Supervision (Aufsicht) von ausgebildeten und sehr erfahrenen Psychotherapeutinnen. Falls die Behandlung nicht zum gewünschten Erfolg führt, können optionale Behandlungsmöglichkeiten mit der Psychotherapeutin/ dem Psychotherapeuten diskutiert werden.

### **Abbruch und Widerrufsrecht**



1  
2  
3 Die Teilnahme an der Studie ist freiwillig. Sie können jederzeit und ohne Angabe eines Grundes Ihre  
4 Einverständniserklärung zurückziehen und aus der Studie aussteigen. Der Rücktritt ist mit keinerlei  
5 Kosten oder Nachteilen verbunden. Es wird weiterhin die Möglichkeit geben, eine ambulante Therapie  
6  
7 an der Hochschulambulanz zu machen. Auf Wunsch können außerdem alle Daten, die im Rahmen der  
8 Studie erhoben wurden, gelöscht werden.  
9

## 10 **Datenschutz**

11  
12  
13 **Personenbezogene Daten während Therapie-Durchlauf:** Die Therapeutinnen und  
14 Therapeuten sind verpflichtet alle personenbezogenen Dokumentationen in einer Therapie-  
15 Akte in abschließbaren Schränken aufzubewahren. Für die Sicherstellung der Qualität der  
16 Behandlung sind u. U. Video-Aufnahmen von Therapiesitzungen notwendig, welche auf einer  
17 passwortgeschützten Festplatte in abgeschlossenen Schränken aufbewahrt werden. Diese  
18 Videos werden nach Abschluss der Studie und nach der Beurteilung der Therapie-  
19 Durchführung zur Qualitätssicherung während der Therapie gelöscht. Therapie-Akten werden  
20 nach Therapie-Ende gemäß den Aufbewahrungsfristen der DSGVO 10 Jahre aufbewahrt.  
21  
22

23 **Kodierliste:** Die Erhebung, Speicherung und Verarbeitung der persönlichen Daten (demographische  
24 Daten wie Alter und Geschlecht, Ergebnisse der Fragebögen und Interviews) erfolgen  
25 pseudonomisiert unter Verwendung eines Codes, ohne Angaben ihres Namens. Es existiert eine  
26 Kodierliste auf Papier (im Institut Psychologie, AG klinische Psychologie und Psychotherapie  
27 Philipps-Universität Marburg), welche Ihren Namen mit Ihrem zugeordneten Code verbindet. Diese  
28 Liste ist nur den Versuchsleiter/innen (Studientherapeutinnen und Studientherapeuten) und dem  
29 Projektleiter zugänglich. Diese Liste wird in einem verschließbaren Schrank aufbewahrt und nach  
30 Abschluss der Studie vernichtet. Ihre Daten sind ab dem Zeitpunkt komplett anonymisiert. Es ist dann  
31 nicht mehr möglich, den Code Ihrem Namen zuzuordnen. Solange diese Liste existiert, können Sie  
32 jederzeit die Löschung Ihrer Daten beantragen. Ab der Löschung der Liste ist dies nicht mehr möglich.  
33  
34

35 **Studien- und Datenqualität:** Zur Qualitätssicherung der Durchführung der Studie werden Studien-  
36 unabhängige Prüferinnen und Prüfer, vorausgesetzt Ihrer schriftlichen Einverständniserklärung zur  
37 Schweigepflichtsentbindung, Einblick in personenbezogene Daten (v.a. Therapie-Sitzungen) nehmen,  
38 um die Durchführung der Therapie zu überprüfen. Weiterhin können mit Ihrer Unterschrift zur  
39 Schweigepflichtsentbindung Supervisorinnen und Supervisoren Einblick in personenbezogene Daten  
40 nehmen (Videos, Akten), um die Studientherapeutinnen und Studientherapeuten bestmöglichst bei der  
41 Therapie-Durchführung zu unterstützen.  
42  
43

44 Diese Befragung wird mit Hilfe des Portals <https://www.soscisurvey.de> durchgeführt. Hierbei werden  
45 folgende zentrale Sicherheitsaspekte berücksichtigt: keine Speicherung der IP-Adressen in den  
46 Logfiles, es findet eine SSL-Verschlüsselung statt und der Server befindet sich in München,  
47 Deutschland. Die detaillierten Hinweise zum Datenschutz können unter folgendem Link nachgelesen  
48 werden: <https://www.soscisurvey.de/index.php?page=privacy>.  
49

## 50 **Ansprechpartner**

51  
52 Diese Studie wird unter Leitung von Herrn Prof. Dr. Winfried Rief, Arbeitsgruppe Klinische  
53 Psychologie und Psychotherapie, Fachbereich Psychologie der Philipps-Universität Marburg,  
54 Gutenbergstraße 18, 35037 Marburg durchgeführt.  
55

56 Ansprechpartner für die Studie sind:

- 57 • Frau M. Sc. Anne-Catherine Ewen (Telefon: 06421 28 24053, E-Mail: [ewen@staff.uni-](mailto:ewen@staff.uni-marburg.de)  
58 [marburg.de](mailto:ewen@staff.uni-marburg.de))  
59  
60

- Herr Dr. Marcel Wilhelm (Telefon: 06421 28 23617, E-Mail: [marcel.wilhelm@staff.uni-marburg.de](mailto:marcel.wilhelm@staff.uni-marburg.de))
- Frau Dr. Pia von Blanckenburg (Telefon: 06421 28 2405, E-Mail: [blanckep@staff.uni-marburg.de](mailto:blanckep@staff.uni-marburg.de))
- Frau Dr. Gaby Bleichhardt (Telefon: 06421 28 2369, E-Mail: [gaby.bleichhardt@staff.uni-marburg.de](mailto:gaby.bleichhardt@staff.uni-marburg.de))
- Frau Dr. Katrin Wambach (Telefon: 06421 28 23681, E-Mail: [wambach@staff.uni-marburg.de](mailto:wambach@staff.uni-marburg.de)) Der verantwortliche Studienleiter,  
Herr Prof. Dr. Winfried Rief (Telefon: 06421 28 23641, E-Mail: [riefw@staff.uni-marburg.de](mailto:riefw@staff.uni-marburg.de)),  
kann ebenfalls bei weiteren Fragen kontaktiert werden.

Wenn Sie alle Informationen gelesen und verstanden haben, die Gelegenheit für Rückfragen hatten und diese angemessen beantwortet wurden, bitten wir Sie Ihre Teilnahme an der Studie mit der Unterschrift auf der beiliegenden Einverständniserklärung zu bestätigen.

Herzlichen Dank!

**Ihr EFFECT-Studien-Team**

**E-Mail:** [effect04@uni-marburg.de](mailto:effect04@uni-marburg.de) **Tel:**06421-22834

## Einverständniserklärung zur Studienteilnahme

Mir wurde von Frau/ Herrn \_\_\_\_\_ ausführlich erklärt, worum es in der EFFECT-Studie geht.

Ich, \_\_\_\_\_ (Name der Teilnehmerin / des Teilnehmers), habe ein Informationsblatt mit näheren Informationen zum Ziel und Ablauf der oben genannten Studie erhalten („Studieninformation“). Ich habe alle Informationen vollständig gelesen und verstanden. Sofern ich Fragen zu der Studie hatte, wurden sie vollständig und zu meiner Zufriedenheit beantwortet.

Ich erkläre mich mit den im Informationsblatt („Studieninformation für Teilnehmerinnen und Teilnehmer“) beschriebenen Erklärungen und Studienbedingungen und mit der beschriebenen Handhabung der erhobenen Daten einverstanden. Ich wurde darüber informiert, dass meine Teilnahme freiwillig ist. Ich weiß, dass ich jederzeit und ohne Angabe von Gründen meine Zustimmung zur Teilnahme widerrufen kann, ohne dass mir dadurch irgendwelche Nachteile entstehen. Wenn die Notwendigkeit besteht, kann ich weiter an einer ambulanten Psychotherapie an der Psychotherapie-Ambulanz Marburg/ Institut für Psychotherapie-Ausbildung Marburg (PAM/ IPAM) teilnehmen. Mir ist bekannt, wie und von wem meine persönlichen Daten im Rahmen der Studie verarbeitet werden. Wenn ich das möchte, weiß ich, dass ich die Löschung meiner Daten einfordern kann.

Eine Ausfertigung der Teilnehmerinformationen und Einwilligungserklärung habe ich erhalten. Ich hatte genügend Zeit eine Entscheidung zu treffen und erkläre mich hiermit bereit, an der oben genannten Studie teilzunehmen.

\_\_\_\_\_ Name des Teilnehmers/ der Teilnehmerin

\_\_\_\_\_ Name des Diagnostikers/ der Diagnostikerin

\_\_\_\_\_ Ort, Datum und Unterschrift des Teilnehmers/ der Teilnehmerin

\_\_\_\_\_ Ort, Datum und Unterschrift des Diagnostikers/ der Diagnostikerin



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	YES
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	YES
	2b	All items from the World Health Organization Trial Registration Data Set	YES
Protocol version	3	Date and version identifier	YES
Funding	4	Sources and types of financial, material, and other support	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	/
	5b	Name and contact information for the trial sponsor	/
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	/(no funder)
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	/
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	YES
	6b	Explanation for choice of comparators	YES
Objectives	7	Specific objectives or hypotheses	YES
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	YES

### Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	YES
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	YES
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	YES
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	YES
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	YES
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	YES
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	YES
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	YES
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	YES
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	YES

### Methods: Assignment of interventions (for controlled trials)

Allocation:

1				
2	Sequence	16a	Method of generating the allocation sequence (eg, computer-	YES
3	generation		generated random numbers), and list of any factors for stratification.	
4			To reduce predictability of a random sequence, details of any planned	
5			restriction (eg, blocking) should be provided in a separate document	
6			that is unavailable to those who enrol participants or assign	
7			interventions	
8				
9				
10	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	YES
11	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
12	mechanism		describing any steps to conceal the sequence until interventions are	
13			assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	YES
16			and who will assign participants to interventions	
17				
18	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	YES
19	(masking)		participants, care providers, outcome assessors, data analysts), and	
20			how	
21				
22				
23		17b	If blinded, circumstances under which unblinding is permissible, and	YES
24			procedure for revealing a participant's allocated intervention during	
25			the trial	
26				
27				
28	<b>Methods: Data collection, management, and analysis</b>			
29				
30	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	YES
31	methods		trial data, including any related processes to promote data quality (eg,	
32			duplicate measurements, training of assessors) and a description of	
33			study instruments (eg, questionnaires, laboratory tests) along with	
34			their reliability and validity, if known. Reference to where data	
35			collection forms can be found, if not in the protocol	
36				
37				
38		18b	Plans to promote participant retention and complete follow-up,	YES
39			including list of any outcome data to be collected for participants who	
40			discontinue or deviate from intervention protocols	
41				
42	Data	19	Plans for data entry, coding, security, and storage, including any	YES
43	management		related processes to promote data quality (eg, double data entry;	
44			range checks for data values). Reference to where details of data	
45			management procedures can be found, if not in the protocol	
46				
47				
48	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	YES
49	methods		Reference to where other details of the statistical analysis plan can be	
50			found, if not in the protocol	
51				
52		20b	Methods for any additional analyses (eg, subgroup and adjusted	YES
53			analyses)	
54				
55		20c	Definition of analysis population relating to protocol non-adherence	YES
56			(eg, as randomised analysis), and any statistical methods to handle	
57			missing data (eg, multiple imputation)	
58				
59				
60	<b>Methods: Monitoring</b>			

1				
2	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	/
3				
4				
5				
6				
7				
8				
9		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	YES
10				
11				
12				
13	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	YES
14				
15				
16				
17	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	YES
18				
19				
20				
21				
22	<b>Ethics and dissemination</b>			
23	<hr/>			
24				
25				
26				
27	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	YES
28				
29				
30	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	YES
31				
32				
33				
34				
35				
36	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	YES
37				
38				
39				
40		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	/
41				
42	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	YES
43				
44				
45				
46				
47	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	/
48				
49				
50	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	YES
51				
52				
53				
54	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	/
55				
56				
57				
58				
59				
60				

1				
2	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	
3				
4				
5				
6				
7		31b	Authorship eligibility guidelines and any intended use of professional writers	YES
8				
9				
10		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	/ (In Preregistration)
11				
12				
13				
14				
15				
16	<b>Appendices</b>			
17				
18	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	YES
19				
20				
21	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	/
22				
23				
24				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Expectation focused and frequency enhanced cognitive behavioral therapy for patients with major depression (EFFECT): A study protocol of a randomized active-control trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-065946.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Feb-2023
Complete List of Authors:	Ewen, Anne-Catherine; Philipps-University Marburg Faculty of Psychology, FB04 Clinical Psychology and Psychotherapy Bleichhardt, Gaby; Philipps-Universität Marburg, Clinical Psychology and Psychotherapy Rief, Winfried; Philipps-Universität Marburg Von Blanckenburg, Pia; Philipps-Universität Marburg, Klinische Psychologie und Psychotherapie Wambach, Katrin; Philipps-Universität Marburg, Clinical psychology and psychotherapy Wilhelm, Marcel; Philipps-Universität Marburg,
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Health policy, Mental health
Keywords:	Depression & mood disorders < PSYCHIATRY, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, MENTAL HEALTH, PSYCHIATRY, Adult psychiatry < PSYCHIATRY, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



1  
2  
3 **Expectation focused and frequency enhanced cognitive behavioral therapy for patients**  
4 **with major depression (EFFECT): A study protocol of a randomized active-control trial**  
5  
6  
7  
8  
9

10 Ewen, A. <sup>a</sup>, Bleichhardt, G. <sup>a</sup>, Rief, W. <sup>a</sup>, von Blanckenburg, P. <sup>a</sup>, Wambach, K. <sup>a</sup> & Wilhelm,  
11  
12 M. <sup>a</sup>  
13

14 <sup>a</sup> Philipps-University of Marburg, Germany, Department clinical psychology and  
15  
16  
17 psychotherapy  
18  
19  
20

21 **Author information:**  
22

23 Corresponding author: Anne-Catherine Ewen, M. Sc.  
24

25  
26 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
27  
28 Gutenbergstraße 18, 35032 Marburg, Germany  
29

30 E-Mail: [ewen@uni-marburg.de](mailto:ewen@uni-marburg.de)  
31

32 Dr. Gaby Bleichhardt  
33

34  
35 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
36  
37 Gutenbergstraße 18, 35032 Marburg, Germany  
38

39 E-Mail: [gaby.bleichhardt@staff.uni-marburg.de](mailto:gaby.bleichhardt@staff.uni-marburg.de)  
40

41 Prof. Dr. Winfried Rief  
42

43  
44 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
45  
46 Gutenbergstraße 18, 35032 Marburg, Germany  
47

48 E-Mail: [rief@staff.uni-marburg.de](mailto:rief@staff.uni-marburg.de)  
49

50 Dr. Pia von Blanckenburg  
51

52  
53 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
54  
55 Gutenbergstraße 18, 35032 Marburg, Germany  
56

57 E-Mail: [blanckep@staff.uni-marburg.de](mailto:blanckep@staff.uni-marburg.de)  
58

59 Dr. Katrin Wambach  
60

1  
2  
3 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
4  
5 Gutenbergstraße 18, 35032 Marburg, Germany  
6

7 E-Mail: [wambach@staff.uni-marburg.de](mailto:wambach@staff.uni-marburg.de)  
8  
9

10 Dr. Marcel Wilhelm  
11

12 Philipps-University of Marburg, department clinical psychology and psychotherapy,  
13  
14 Gutenbergstraße 18, 35037 Marburg, Germany  
15

16  
17 E-Mail: [marcel.wilhem@staff.uni-marburg.de](mailto:marcel.wilhem@staff.uni-marburg.de)  
18  
19  
20

## 21 **Abstract**

22  
23 **Introduction.** The effectiveness of psychotherapy in depression is subject of an  
24 ongoing debate. The mechanisms of change are still underexplored. Research tries to find  
25 influencing factors fostering the effect of psychotherapy. In that context, the dose-response  
26 relationship should receive more attention. Increasing the frequency from one to two sessions  
27 per week seems to be a promising start. Moreover, the concept of expectations and its  
28 influence in depression can be another auspicious approach. Dysfunctional expectations and  
29 the lack of their modification are central in symptom maintenance. Expectation focused  
30 psychological interventions (EFPI) have been investigated, primarily in the field of  
31 depression. The aim of this study is to compare cognitive behavioral therapy (CBT) once a  
32 week with an intensified version of CBT (twice a week) in depression as well as to include a  
33 third proof-of-principle intervention group receiving a condensed expectation focused CBT.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **Methods and Analysis.** Participants are recruited through an outpatient clinic in  
50 Germany. A current major depressive episode, diagnosed via structured clinical interviews  
51 should present as the main diagnosis. The planned randomized-controlled trial will allow  
52 comparisons between the following treatment conditions: CBT (1 session/week), condensed  
53 CBT (2 sessions/week), and EFPI (2 sessions/week). All treatment arms include a total dose  
54 of 24 sessions. Depression severity applies as the outcome variable (Beck Depression  
55  
56  
57  
58  
59  
60

1  
2  
3 Inventory II; BDI-II, Montgomery Asberg Depression Rating Scale; MADRS). A sample size  
4  
5 of n=150 is intended.  
6

7 **Ethics and dissemination.** The local ethics committee of the Department of Psychology,  
8  
9 Philipps-University Marburg approved the study (reference number 2020-68v). The final  
10  
11 research article including the study results is intended to be published in international peer-  
12  
13 reviewed journals.  
14  
15

16  
17  
18  
19 **Key words.** cognitive behavioral therapy (CBT), once vs. twice weekly sessions,  
20  
21 expectation focused psychological interventions (EFPI), depression, psychotherapy research  
22

### 23 **Strengths**

- 24 • Practice-oriented randomized controlled design to test the effectiveness of  
25  
26 psychotherapy  
27
- 28 • the results will add important information to the research body of structural conditions  
29  
30 for psychotherapy, allowing further conclusions on how often psychotherapy should  
31  
32 be offered  
33
- 34 • First study that includes expectation focused psychological interventions (EFPI)  
35  
36 assuming dysfunctional expectations as main mechanisms of symptom persistence and  
37  
38 the lack of change  
39  
40  
41  
42  
43

### 44 **Limitations**

- 45 • As this is a manualized psychotherapy study designed for depression, the transfer to  
46  
47 other disorders may be limited  
48
- 49 • For economic reasons, it was opted against a 2 x 2 design, including only three  
50  
51 treatment arms: CBT once weekly, CBT twice weekly, EFPI twice weekly  
52  
53  
54  
55  
56  
57

## 58 **Theoretical background**

59  
60

1  
2  
3 Major depression, as one form of mood disorders, is one of the most common mental  
4 disorders with a lifetime prevalence of 13 % in Europe [1]. In the last decades, research  
5 seemed to prove the effectiveness of different treatments for depression [2-5]. However, a  
6 meta-analysis reassessing the effects of psychotherapy for adult depression with the aim to  
7 control methodological biases in meta-analyses puts the effectiveness into question again [6,  
8 7]. The need to find promising approaches to enhance effectiveness seems obvious. However,  
9 treatment research that compares the different psychotherapy procedures with different  
10 theoretical backgrounds aiming to find the best techniques might have reached its limits [8].  
11 A long line of research started to focus on common or unspecific factors leading to treatment  
12 success. Typical common factors are therapeutic relationship or alliance, treatment  
13 expectations, empathy and congruence [9, 10]. Especially the concept of expectations is  
14 receiving more and more attention as an important factor in psychopathology [11].

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Furthermore, the consideration of common structural variables such as the number of  
32 sessions, duration of sessions, or environmental factors was rather neglected. It not only  
33 seems important to consider these factors to augment positive treatment outcome, but also to  
34 define an evidence-based professional policy of psychotherapy in healthcare systems. Even in  
35 Germany, as one of the few European countries where psychotherapy is paid by health  
36 insurance, a length of twelve to sixty one-weekly 50-minute session for cognitive behavioral  
37 therapy is the default [12]. With exception of the duration, the frequency of sessions per week  
38 seems to be rather randomly determined due to convenience and a lack of evidence.

39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 In the last years psychotherapy researchers started investigating the dose-response  
50 relationship [13-15]. As “dose”, different factors can be considered, e.g., total number of  
51 sessions, number of sessions per week, or the session duration. Howard and colleagues [16]  
52 were one of the first to look at the number of sessions needed to reach symptom recovery by  
53 calculating a probit model (dose-response model). After eight sessions, 50% of the patients  
54 showed symptom improvement, whereas 75% of the patients improved after 26 sessions.  
55  
56  
57  
58  
59  
60

1  
2  
3 Further evidence confirms the need of approximately 20 sessions to expect a symptom  
4 recovery by over half to two-thirds of the patients [14, 15, 17, 18]. The change pattern seems  
5 to be negatively accelerated, as a greater effect per session occurs in earlier sessions, which  
6 then decreases in the later sessions [19-21].  
7  
8  
9  
10

11  
12 A meta regression analysis showed no significant influence of the duration of the  
13 therapy, while replacing one session per week by two sessions per week increased the effect  
14 by a small to medium effect size [22]. Some studies already showed a positive effect of higher  
15 session frequency leading to faster recovery [23-25]. Erekson and colleagues [25] for example  
16 showed in a naturalistic setting that a counseling session every week compared to a decreased  
17 frequency not only leads to a faster change, but also to a higher likelihood of achieving  
18 recovery and achieving it sooner. Moreover, these findings were also supported by an RCT  
19 comparing one versus two sessions per week, concluding that two weekly sessions in clinical  
20 practice could improve treatment outcome in depression [13]. A higher session frequency  
21 seems to result in a faster recovery, making it a promising variable to improve the efficiency  
22 of psychotherapy [26].  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Only very few studies dealt with the comparison of intensive and standard treatment  
38 regarding the duration of one therapy session. Especially for anxiety disorders, studies are  
39 indicating mixed results about the superiority of intensive treatment forms, especially in the  
40 long term [27-29]. In conclusion, it seems more promising to increase the frequency (i.e., two  
41 single sessions weekly) of psychotherapy instead of planning double length sessions.  
42  
43  
44  
45  
46  
47  
48

49 As mentioned above, the concept of expectation and its role in psychopathology  
50 should be better considered. The concept of expectations in psychological research leads back  
51 to action and decision making theories [30-32]. A consistent definition is still lacking [33].  
52 Humans learn through constant prediction updating based on external input [34-36].  
53 Experiences lead to the development of specific expectations towards future events and  
54 proper behavior [37, 38]. However, expectations are not only unidirectionally formed by the  
55  
56  
57  
58  
59  
60

1  
2  
3 external input through experiences. They also influence the experience in future situations  
4  
5 beforehand, as it is well-observed in the so-called placebo effects [39-41]. Some studies  
6  
7 analyzed the relationship between initial expectation change and treatment outcome [42-44].  
8  
9  
10 As already mentioned above, initial positive outcome expectations are associated to a better  
11  
12 treatment outcome, whereas inducing positive outcome expectations or changing negative  
13  
14 ones change significantly the treatment outcome in a positive way. Thus, expectations play a  
15  
16 central role in psychotherapy, regarding the therapy outcome [45, 46] or the therapeutic  
17  
18 relationship [47, 48].  
19  
20

21  
22 According to the underlying theoretical models [49-51], the lack of expectation  
23  
24 adaptation after expectation violating information is defined as fundamental. This is mainly  
25  
26 explained through two mechanisms: the minimization of the importance of expectation-  
27  
28 disconfirming evidence and the search for or the production of future expectation-confirming  
29  
30 evidence [52]. The ViolEx-model [11, 49, 53], adapted by Panitz and colleagues in 2021 [51],  
31  
32 describes the different processes of expectation adaptation or persistence and transfers it to  
33  
34 psychopathology. The model hypothesizes that general expectations are formed by the social  
35  
36 environment, individual differences (e.g., personality traits), and past experiences. These  
37  
38 general expectations form situation-specific expectations. Furthermore, different anticipatory  
39  
40 reactions are described to highlight different processes influencing the situational outcome  
41  
42 (e.g., attention steering to expectation-confirming cues rather than to expectation-  
43  
44 disconfirming cues). A differentiation between internal (i.e., preparation to the situation) and  
45  
46 external reactions (i.e., assimilation, or experimentation, approach, or avoidance) are made.  
47  
48  
49 Assimilation is described as the process of the attempt to confirm the expectation whereby  
50  
51 experimentation is defined as the process of wanting to openly collect valid data to check the  
52  
53 proper expectation. Transferring this to psychopathology, assimilation can include avoidant  
54  
55 behavior as is well known in anxiety disorders [54, 55]. Experimentation is a process that is  
56  
57 desired in psychotherapy to adapt dysfunctional or unhelpful thoughts [56, 57]. If the  
58  
59  
60

1  
2  
3 expectation is violated through an unexpected experience, the initial expectation should be  
4 adapted or at least questioned (i.e., accommodation). This process is often blocked, especially  
5 in patients with depression [58]. The ViolEx raises a concept called *cognitive immunization*,  
6 which can lead to expectation persistence. The process of cognitive immunization, i.e., the  
7 reappraisal of disconfirming information in order to maintain prior expectations, is  
8 demonstrated in first experimental designs, especially in people with depressive symptoms  
9 [58-60]. Depressed patients show increased dysfunctional expectations and at the same time a  
10 lack of ability to accommodate these dysfunctional expectations after new expectation-  
11 disconfirming experiences [50, 61]. This was already described in the context of learned  
12 helplessness as a fundamental explanatory model of depression [62]. Different processes seem  
13 to inhibit expectation adaptation by expectation-inconsistent experiences, leading to rigid  
14 expectations and thinking [63].

15  
16 Integrating expectation focused psychological interventions (EFPI) into psychotherapy  
17 to directly address processes leading to expectation persistence is the next logical step [64,  
18 65]. Based on the presented theoretical background, mechanisms that lead to rigid thought  
19 patterns (e.g., anticipatory reactions or immunization processes) should be made salient,  
20 whereby a destabilization or change of psychopathological expectations and an experimenting  
21 behavior should be fostered. This entails the possibility to integrate new (positive)  
22 experiences in future expectations. Kolb and colleagues [66] emphasize that individuals  
23 should make new experiences to learn. It therefore seems crucial to support patients in  
24 making new experiences and to facilitate learning processes that challenge problem-specific  
25 expectations. Moreover, making information processing mechanisms (i.e., not only  
26 assimilation but also immunization) salient in psychotherapy allows the patients to not only  
27 change unhelpful expectations, but also learn to actively influence their processing  
28 mechanisms. According to Rief and colleagues [53], effective therapy needs to include  
29 successful expectation violations to change dysfunctional expectations that are related to the  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 development and/ or maintenance of psychopathology (as for example negative expectations  
4 in depression [61, 67, 68]). Based on this rational, therapy resistance may be counteracted by  
5 directly addressing immunization processes that are hypothesized to play a crucial role [53,  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

development and/ or maintenance of psychopathology (as for example negative expectations in depression [61, 67, 68]). Based on this rational, therapy resistance may be counteracted by directly addressing immunization processes that are hypothesized to play a crucial role [53, 68]. All these processes described by the ViolEx model are usually not directly addressed in psychotherapy. As major depression is one of the most prevalent mental disorders, this study aims to find possible ways to foster psychotherapy by firstly specifying the necessary frequency for an effective psychotherapeutic treatment in depression and, secondly prove the effectiveness of expectation focused cognitive behavioral therapy in depression.

For this study, three concrete hypotheses are formulated:

1. A standard CBT protocol leads to a higher reduction in depressive symptoms when applied twice weekly, compared to one session a week.
2. As a pilot, an innovative CBT program focusing and providing expectation-focused interventions (EFPI), also applied twice weekly, should lead to a significant reduction in depressive symptoms over time.
3. The EFPI condition approaching expectations as core mechanisms with two sessions a week will show a superiority over the CBT condition twice weekly.
4. Dysfunctional expectations will have a higher impact on the therapy outcome in the EFPI condition than in the CBT condition.

## Methods

### Ethics and dissemination

The local ethics committee of the Department of Psychology, Philipps-University Marburg approved the study (reference number 2020-68v), which was pre-registered under drks.de (German Clinical Trials Register DRKS00023203). The final research article including the study results is intended to be published in an international peer-reviewed journal with the possibility of open access.

### Patient and Public involvement



1  
2  
3 Patients were primarily involved in the preparation of the study manuals (especially  
4 EFPI). Patients in treatment due to depression were giving input and feedback about the  
5 different interventions chosen and / or developed by the study investigators. We intend to  
6 provide the main results of the study to interested participants.  
7  
8  
9  
10

### 11 **Population**

12 Participant recruitment is planned between October 2020 and December 2023.  
13  
14 Participants will mainly be recruited at the psychotherapy outpatient clinic (Psychotherapie  
15 Ambulanz Marburg; PAM) of the Philipps-University Marburg. If a current major depression  
16 episode is suspected in the initial interview, the patient will be informed about this study. The  
17 following inclusion criteria should be met: participants should be at least 18 years, have a  
18 sufficient knowledge of German, have a major depression episode according to DSM-IV as  
19 the main diagnosis and should fulfill a total BDI-II score over 13 (mild depression). Patients  
20 were excluded if they have had a psychotic disorder (now or in the past) or are addicted to  
21 substances such as alcohol, drugs, medication. Moreover, if psychopharmacological drugs are  
22 prescribed, the intake dose must be stable over the last 4 weeks and not be changed during the  
23 treatment and first follow-up phase. In accordance to Bruijniks and colleagues [13], a total  
24 sample size of 150 participants is planned (with a supposed small effect size of 0.25 and a  
25 alpha of 0.05, a power of 0.92 can be reached with a sample size of 150 by considering  
26 repeated measures, within-between interaction).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **Study Design and procedure**

47 Patients who are interested in study participation undergo a short telephone interview  
48 on the inclusion criteria and are then invited to a diagnostic appointment. The inclusion and  
49 exclusion criteria are then thoroughly checked. If the inclusion criteria are met, the study  
50 procedure is explained, and an informed consent (see Appendix A1) form is signed. The  
51 patients are randomly assigned by one study leader following simple randomization  
52 (computerized random numbers) to one of the three groups and assigned to a study therapist.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A coding list is maintained by one of the study leaders during the ongoing study and is going  
4 to be deleted after study completion. The first six sessions are used as a run-in phase for  
5 assessments and establishing a therapeutic relationship, as well as the collection of further  
6 questionnaires and clinical history to confirm the diagnosis. The run-in phase is six weeks,  
7 frequency and content are independent of the treatment condition. They consist out of  
8 anamnesis (e.g., with the help of lifeline) and information gathering to draw a micro and  
9 macro functional analysis [69]. There are no interventions allowed during the run-in phase.  
10 Subsequently, the twenty-four therapy sessions start. Twenty-four sessions are chosen to  
11 match the German health care plan of a short-term therapy and is in line with the literature  
12 presented in the introduction about the number of sessions needed to expect recovery.  
13 Depending on the treatment condition, one respectively two therapy sessions take place per  
14 week. For those having appointments twice a week, the last four therapy sessions are spread  
15 over 10 weeks (see figure 1). Moreover, a diagnostic interview is conducted after the  
16 twentieth and twenty-fourth session. After the end of twenty-four sessions, a first follow-up  
17 diagnostic interview takes place after three months of the last (24<sup>th</sup>) session. In that time, no  
18 therapeutic sessions are allowed, and antidepressant medication should be kept stable.  
19 Afterwards, further sessions can be conducted if necessary (e.g., for the treatment of  
20 secondary diagnosis or uncovered symptoms). A second follow-up diagnostic interview is  
21 planned two years after the end of study treatment (see figure 2).

### 22 **Diagnostic assessments**

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Psychotherapists in post gradual training conduct the diagnostic interviews and are blinded to the condition. In the case of unblinding, the following diagnostic assessments will be conducted by another, still blinded, diagnostician. The diagnostic interviews are supervised by licensed therapists and supervisors. The first diagnostic interview consists of the study information, the informed consent, the implementation of the German version of the structural clinical interview for DSM-IV [70], and the BDI-II [71] by the client and the MADRS [72] by

1  
2  
3 the diagnostician. In the following diagnostic interviews, only the major depression section of  
4 the SCID-IV is conducted to rate the MADRS. These external assessments by the  
5  
6 the SCID-IV is conducted to rate the MADRS. These external assessments by the  
7  
8 diagnosticians take place at baseline, after the twentieth and twenty-fourth therapy session, as  
9  
10 well as after three months and two years after therapy completion. All self-rating  
11  
12 questionnaires are answered after the sessions on a tablet using SoScisurvey [73].  
13

### 14 **Type of Treatments**

15  
16 All therapists conducting the study therapy are psychotherapists in training and receive  
17  
18 regular supervision (after every fourth therapy session). The first cohort of study therapists  
19  
20 receives a workshop on the different treatment conditions and the study flow. The workshop  
21  
22 is recorded to easily train new study therapists when needed. All therapists will receive a  
23  
24 standardized training and are scheduled to deliver treatment in all three conditions at least  
25  
26 once to balance out therapist effects.  
27  
28  
29

30  
31 In total, the study includes three treatment samples (see appendix A2). First, the  
32  
33 treatment-as-usual (TAU) group consists of one CBT session per week (TAU CBT). The  
34  
35 second group receives a more condensed CBT version with two CBT sessions per week  
36  
37 during the main parts of treatment (CBT condensed). The third group also receives two  
38  
39 sessions per week, but the CBT approach is based on expectation focused psychological  
40  
41 interventions (EFPI condensed). For the second and third condition, the last four sessions are  
42  
43 spread over 10 weeks. After twenty-four sessions, the treatment according to study protocol is  
44  
45 completed. As mentioned above, continuation of therapy, is possible after the 3-months  
46  
47 follow up if necessary. After two years, a second follow-up measurement will take place to  
48  
49 estimate long-term therapy effectiveness.  
50  
51  
52

53  
54 **CBT manual.** The manual is based on the most common CBT manuals, which are  
55  
56 already implemented in practice [74-76]. It firstly includes a description of the attitude and  
57  
58 behavior of a CBT therapist [77]. The manual is modularized and enables personalization by a  
59  
60 selection of up to three out of seven possible, problem-specific CBT modules. The first

1  
2  
3 session deals with psychoeducation on depression. Typical symptoms are collected, and an  
4 individual case concept is developed including cognitions, feelings, and behavior. The seven  
5 modules include inactivity, cognitive work, relaxation, problem solving, emotion regulation,  
6 interpersonal difficulties, and self-esteem. Every module starts with a psychoeducational part  
7 linking the patient's own problems with the respective module. Further on, worksheets are  
8 presented, which were designed according to suggestions of different CBT-manuals for  
9 depression [77-79]. The manual closes in session 24 with relapse prevention.

10  
11  
12  
13  
14  
15  
16  
17  
18  
19 **EFPI manual.** Even though the EFPI manual is based on cognitive-behavioral  
20 interventions, it was decided to test the manual for feasibility first. Therefore, two therapists  
21 in training executed the manualized therapy with two voluntary patients and constantly  
22 consulted with the supervisor and the patient. The manual was slightly updated based on the  
23 comments of the therapists, supervisor, and patients.

24  
25  
26  
27  
28  
29  
30  
31 In the first six sessions, psychoeducation on the link between expectations and  
32 depressive symptoms is delivered. Participants should acquire knowledge about expectations  
33 as a specific form of thoughts and how expectations regulate human behavior. The advantages  
34 (e.g., fast behavior planning) and disadvantages (e.g., reduced flexibility) of forming  
35 expectations are elaborated. The negative consequences of very rigid expectations are  
36 discussed. Through self-observation, personal expectations should be made salient. Explicit  
37 expectations concerning the therapy are addressed. Further on, the link between the patient's  
38 biography and the origin of their expectations is drawn. An introduction to behavioral  
39 experiments as an important tool to test, break, and change dysfunctional expectations is  
40 introduced. Cognitive immunization, as a mechanism of reappraising new information to fit  
41 into prior expectations and to prevent expectation change despite contradicting experiences, is  
42 explained, and introduced based on the patient's personal examples.

43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

After the psychoeducation phase, behavioral experiments are to be planned and conducted with the aim to test dysfunctional expectations considering the patient's

1  
2  
3 immunization strategies. In contrast to the possible performed behavioral experiments in the  
4  
5 CBT condition, the focus in the EFPI condition lies on the understanding of the information  
6  
7 processing mechanisms and, consequently, taking control over these by the possibility to  
8  
9 actively influence them. The behavioral experiments in the EFPI condition are a new  
10  
11 information processing strategy learned by the patients, rather than a strategy to change the  
12  
13 content of expectations. The manual gives examples on behavioral experiments for different  
14  
15 depression specific problems (parallel to modules CBT manual). The therapists are supposed  
16  
17 to be very flexible in planning behavioral experiments. It is obligatory to carry out at least one  
18  
19 behavior experiment between (or within) each session. For relapse prevention, which is  
20  
21 addressed in the 24<sup>th</sup> session, the prior expectations towards therapy are reviewed, learned  
22  
23 strategies are collected, and future plans are elaborated.

### 24 25 26 27 28 **Assessments**

29  
30 The timepoints of the different assessments used are summarized in table 1.

31  
32  
33 **Demographic variables.** Different variables about the participants will be assessed  
34  
35 including gender, age, nationality, mother language, education, and occupation.

36  
37  
38 **Primary outcome.** To analyze symptom reduction the self-rating scale Beck  
39  
40 Depression Inventory II – German Version [71] is used, as well as the expert rating scale  
41  
42 Montgomery Asberg Depression Rating Scale MADRS [72]. The MADRS is a ten-item  
43  
44 questionnaire for clinicians to rate depressive symptoms on a seven-rating scale while the  
45  
46 patient is interviewed by them. Again, a higher sum-score indicates a more severe depression.  
47  
48 A sum score of 0 to 7 means no depression, 7 to 19 indicates a mild depression, 20 to 34  
49  
50 moderate and a sum score over 34 is noted as severe depression.

51  
52  
53  
54 **Secondary outcome.** Dysfunctional expectations are assessed with the depressive  
55  
56 expectations scale DES [61]. To assess the general symptom burden, the revised German  
57  
58 version of the symptom checklist SCL-90 [80] is used. With ninety items, different symptoms  
59  
60 are assessed that are grouped into following subscales: somatization, compulsivity,

1  
2  
3 depression, insecurity in social contact, anxiety, aggression, phobia, paranoia, psychoticism.  
4  
5 Using 25 items, dysfunctional expectations about social rejection, social support, mood  
6  
7 regulation, and ability to perform are assessed. The therapeutic alliance is assessed with the  
8  
9 helping alliance questionnaire HAQ [81] integrating two eleven-item questionnaires, one for  
10  
11 the patient and one for the clinician asking about the therapeutic relationship. To assess  
12  
13 specific expectations towards the treatment, the six-item credibility/expectancy questionnaire  
14  
15 CEQ [82] is used.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Overview of the study instruments and the survey timepoints.

Domain	Instrument	Inclusion diagnostic	Probatory (6 sessions)	T 10	T20	T24	FU 1 after 3 moths	FU 2 after 2 years
Demographic and amnestic information	demographics	x	x					
Depressive symptom severity	BDI-II	x	x	x	x	x	x	x
	MADRS	x			x	x	x	x
	SCID-IV	x						
General symptoms	SCL-90		x	x	x	x	x	
Therapeutic alliance	HAQ		x	x	x	x	x	
Expectations and immunization	CEQ		x	x	x	x	x	x
	DES		x	x	x	x	x	x
Analogue scales about homework, engagement, actual impairment, actual expectation towards treatment, negative expectations	self-formulated items	x	x	x	x	x	x	x

Note. BDI-II Beck Depression Inventiory, MADRS Montgomery Asperg Rating Scale, SCID-IV structural clinical interview for DSM-IV, SCL-90 Symptom Checklist, HAQ Helping Alliance Questionnaire, CEQ Credibility and Expectancy Questionnaire, DES Depressive Expectation Scale, IMS Immunization Scale; Analogue scales are assessed for every therapeutic session as momentary assessment

1  
2  
3  
4  
5 To test for acceptance, drop-out rates will be compared between the three conditions.  
6  
7 Treatment adherence will be controlled by analyses of the recorded sessions by study  
8  
9 independent raters.  
10

### 11 **Every-session monitoring.**

12  
13  
14 In every therapy session, patients are supposed to answer questions regarding  
15  
16 homework completion, engagement (“From the last session to this one, my commitment to  
17  
18 therapy was”: extremely low to extremely high 0-100), depressive symptoms [83], and their  
19  
20 own expectations [82] to monitor treatment progress. The questions were adapted by the  
21  
22 authors for the progress diagnostics.  
23

### 24 **Statistical Analysis**

25  
26  
27 The complete anonymous dataset including all important subject data is regularly  
28  
29 supplemented during the ongoing study (a.o., demographics, protocol violations, completed  
30  
31 questionnaires). Intention-to-treat analyses are planned. At first, missing values and dropouts  
32  
33 will be analyzed regarding their distribution. Due to clustered data as well as a certain  
34  
35 estimated amount of missing data and a continuous time variable, mixed models for repeated  
36  
37 measures shall be calculated [84]. In accordance with the study of Bruijniks and colleagues  
38  
39 [13], multilevel analyses will be calculated to analyze the frequency condition (once vs. twice  
40  
41 weekly), as well as the intervention form (CBT vs. EFPI) on depressive symptoms (BDI-II  
42  
43 scores and MADRS scores) over the treatment time first including the interaction terms time x  
44  
45 frequency and time x treatment. To analyze if the frequency effect will differ between therapy  
46  
47 forms, a second model with the interaction term time x frequency x intervention will be  
48  
49 calculated. Significance levels will be set at  $p < 0.05$ . The same models will be used for  
50  
51 secondary outcomes and moderator analyses. Further on, effect sizes (Cohen’s  $d$ ) will be  
52  
53 calculated.  
54  
55  
56  
57  
58  
59  
60

### **Discussion**



1  
2  
3 This study will analyze the influence of session frequency, as well as the influence of  
4 specific expectations on psychotherapy effectiveness. Strengths and limitations are discussed  
5 in the following.  
6  
7  
8  
9

10 **Limitations.** To standardize the treatment groups, a CBT manual as well as an EFPI  
11 manual were written. Depression is known as a highly comorbid disorder [85, 86], the manual  
12 might not be flexible enough. To counteract the limitation, the CBT manual was modularized,  
13 so the therapists have the possibility to choose personalized modules. For the EFPI manual,  
14 only the psychoeducation sessions are completely predefined, whereas the chosen topics in  
15 therapy are mutually defined by patients and therapists. The only specification by the protocol  
16 is that at least one behavioral experiment must be conducted in / between every session. In  
17 that sense, the authors support the increasing idea of tailoring psychotherapy to the person  
18 [87]. As the EFPI treatment is still in its pilot phase and as to avoid underpowered samples,  
19 we opted against a 2 x 2 design, and for the neglect of an EFPI once weekly condition.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 **Strengths.** This study has a well-structured randomized controlled design, whereas  
34 the execution of the study is very practice oriented and naturalistic. The study directly  
35 addresses the structure of care, allowing people with mental health problems to be helped  
36 quickly. The study therapists are all in their psychotherapist training, whereby differences in  
37 psychotherapeutic experience and other therapeutic differences are tried to be kept low, as it  
38 is done by the randomization. They are all supervised by CBT- or EFPI-supervisors.  
39  
40 Moreover, the innovative expectation focused therapy manual can be compared directly to a  
41 well-established and evidence-based psychotherapy form. We will also evaluate one treatment  
42 arm focusing on the maintenance and change of problem-specific expectations. Such a focus  
43 promises powerful efficacy, because of its close relation to brain functions, central treatment  
44 mechanisms, and mechanisms of change.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 **Expected benefit.** Important implications for therapy session frequency can be drawn  
59 to create optimal learning conditions. We address the practical execution of psychotherapy  
60

1  
2  
3 and may suggest a certain guideline concerning the frequency of psychotherapy sessions per  
4 week. If we confirm existing literature, psychotherapy should be implemented in a shorter  
5 time with a two-sessions-per-week-dose. This would especially contribute to reduced waiting  
6 time for psychotherapy. In Germany, the waiting time amounted to twenty weeks in 2018  
7 [88], whereas during the COVID pandemic the time is estimated to increase constantly [89].  
8  
9

10  
11  
12 Further on, this study will be the first one delivering information on the feasibility of  
13 an expectation focused therapy manual in depression. Well-established questionnaires  
14 measuring dysfunctional expectations as well as immunization are not available yet, whereas  
15 first attempts to operationalize the concepts have been made [61]. Further research should  
16 foster valid instruments assessing and validating the constructs of the ViolEx-model. The  
17 EFPI intervention promises to be a theory-driven intervention, based on the ViolEx model  
18 considering disorder-unspecific common factors, with a clear treatment focus that can result  
19 in very powerful effects [42].  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Contributorship statement**  
6

7 **Anne-Catherine Ewen:** Conceptualization, Writing – Original draft, Project administration  
8

9  
10 **Gaby Bleichhardt:** Conceptualization, Writing – Review & Editing, therapist supervision  
11

12 **Winfried Rief:** Conceptualization, Supervision, Writing – Review & Editing **Pia von**  
13

14 **Blanckenburg:** Conceptualization, Writing – Review & Editing **Katrin Wambach:**  
15

16 Conceptualization, Writing – Review & Editing, therapist supervision **Marcel Wilhelm:**  
17

18 Conceptualization, Writing – Review & Editing, Supervision, Project administration  
19

20  
21 **Competing interests:** No conflict of interest to report.  
22

23  
24 **Funding:** This study is not funded.  
25

26 **Data Availability Statement:** Upon reasonable request, data will be made available by the  
27 authors.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Literature

1. Investigators, E.M., et al., *Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project*. Acta psychiatrica scandinavica, 2004. **109**: p. 21-27.
2. De Maat, S., et al., *Relative efficacy of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis*. Psychotherapy Research, 2006. **16**(5): p. 566-578.
3. Ekers, D., D. Richards, and S. Gilbody, *A meta-analysis of randomized trials of behavioural treatment of depression*. Psychological Medicine, 2008. **38**(5): p. 611-623.
4. Gloaguen, V., et al., *A meta-analysis of the effects of cognitive therapy in depressed patients*. Journal of affective disorders, 1998. **49**(1): p. 59-72.
5. Arroll, B., et al., *Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis*. The Annals of Family Medicine, 2005. **3**(5): p. 449-456.
6. Cuijpers, P., et al., *Was Eysenck right after all? A reassessment of the effects of psychotherapy for adult depression*. Epidemiology and Psychiatric Sciences, 2019. **28**(1): p. 21-30.
7. Cuijpers, P., et al., *How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence*. World psychiatry, 2016. **15**(3): p. 245-258.
8. Luborsky, L., et al., *The dodo bird verdict is alive and well--mostly*. 2002.
9. Wampold, B.E., *How important are the common factors in psychotherapy? An update*. World Psychiatry, 2015. **14**(3): p. 270-277.
10. Nahum, D., C.A. Alfonso, and E. Sönmez, *Common factors in psychotherapy*, in *Advances in psychiatry*. 2019, Springer. p. 471-481.
11. Rief, W., et al., *Expectancies as core features of mental disorders*. Current opinion in psychiatry, 2015. **28**(5): p. 378-385.
12. Bundesausschuss, G., *Psychotherapie-Richtlinie*. 2009, Bundesanzeiger.
13. Bruijniks, S.J.E., et al., *The effects of once- versus twice-weekly sessions on psychotherapy outcomes in depressed patients*. The British Journal of Psychiatry 2020: p. 1-9.
14. Harnett, P., A. O'Donovan, and M.J. Lambert, *The dose response relationship in psychotherapy: Implications for social policy*. Clinical Psychologist, 2010. **14**(2): p. 39-44.
15. Hansen, N.B., M.J. Lambert, and E.M. Forman, *The psychotherapy dose-response effect and its implications for treatment delivery services*. Clinical Psychology-Science and Practice, 2002. **9**(3): p. 329-343.
16. Howard, K.I., et al., *The dose-effect relationship in psychotherapy*. American psychologist, 1986. **41**(2): p. 159.
17. Anderson, E.M. and M.J. Lambert, *A survival analysis of clinically significant change in outpatient psychotherapy*. Journal of Clinical Psychology, 2001. **57**(7): p. 875-888.
18. Hansen, N.B. and M.J. Lambert, *An evaluation of the dose-response relationship in naturalistic treatment settings using survival analysis*. Mental Health Services Research, 2003. **5**(1): p. 1-12.

19. Barkham, M., et al., *Dose–effect relations in time-limited psychotherapy for depression*. Journal of consulting and clinical psychology, 1996. **64**(5): p. 927.
20. Kopta, S.M., et al., *Patterns of symptomatic recovery in psychotherapy*. Journal of consulting and clinical psychology, 1994. **62**(5): p. 1009.
21. Robinson, L., J. Delgadillo, and S. Kellett, *The dose-response effect in routinely delivered psychological therapies: A systematic review*. Psychotherapy Research, 2020. **30**(1): p. 79-96.
22. Cuijpers, P., et al., *How much psychotherapy is needed to treat depression? A meta-regression analysis*. Journal of Affective Disorders, 2013. **149**(1-3): p. 1-13.
23. Erekson, D.M., M.J. Lambert, and D.L. Eggett, *The relationship between session frequency and psychotherapy outcome in a naturalistic setting*. Journal of Consulting and Clinical Psychology, 2015. **83**(6): p. 1097.
24. Reese, R.J., M.D. Toland, and N.B. Hopkins, *Replicating and extending the good-enough level model of change: Considering session frequency*. Psychotherapy Research, 2011. **21**(5): p. 608-619.
25. Erekson, D.M., et al., *Psychotherapy session frequency: A naturalistic examination in a university counseling center*. Journal of Counseling Psychology, 2022. **69**(4): p. 531.
26. Erekson, D.M., M.J. Lambert, and D.L. Eggett, *The Relationship Between Session Frequency and Psychotherapy Outcome in a Naturalistic Setting*. Journal of Consulting and Clinical Psychology, 2015. **83**(6): p. 1097-1107.
27. Abramowitz, J.S., E.B. Foa, and M.E. Franklin, *Exposure and ritual prevention for obsessive-compulsive disorder: Effects of intensive versus twice-weekly sessions*. Journal of Consulting and Clinical Psychology, 2003. **71**(2): p. 394-398.
28. Herbert, J.D., et al., *Standard versus extended cognitive behavior therapy for social anxiety disorder: A randomized-controlled trial*. Behavioural and Cognitive Psychotherapy, 2004. **32**(2): p. 131-147.
29. Bohni, M.K., et al., *A randomized study of massed three-week cognitive behavioural therapy schedule for panic disorder*. Acta Psychiatrica Scandinavica, 2009. **120**(3): p. 187-195.
30. Atkinson, J.W. and N.T. Feather, *A theory of achievement motivation*. Vol. 66. 1966: Wiley New York.
31. Kahneman, D. and A. Tversky, *Prospect Theory of Decisions Under Risk*. Econometrica, 1979. **47**(2): p. 1156-67.
32. Ajzen, I., *From intentions to actions: A theory of planned behavior*, in *Action control*. 1985, Springer. p. 11-39.
33. Laferton, J.A., et al., *Patients' expectations regarding medical treatment: a critical review of concepts and their assessment*. Frontiers in psychology, 2017. **8**: p. 233.
34. Berg, M., M. Feldmann, and T. Kube, *Oversampled and undersolved: Depressive rumination from a predictive coding perspective*. 2021.
35. Smith, R., et al., *A Bayesian computational model reveals a failure to adapt interoceptive precision estimates across depression, anxiety, eating, and substance use disorders*. PLoS computational biology, 2020. **16**(12): p. e1008484.
36. Visalli, A., et al., *Bayesian modeling of temporal expectations in the human brain*. Neuroimage, 2019. **202**: p. 116097.
37. Bandura, A., *Self-efficacy: toward a unifying theory of behavioral change*. Psychological review, 1977. **84**(2): p. 191.
38. Lightsey, R., *Albert Bandura and the exercise of self-efficacy*. Journal of Cognitive Psychotherapy, 1999. **13**(2): p. 158.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
39. Evers, A.W., et al., *Implications of placebo and nocebo effects for clinical practice: expert consensus*. *Psychotherapy and psychosomatics*, 2018. **87**(4): p. 204-210.
40. Kirsch, I., *Response expectancy theory and application: A decennial review*. *Applied and preventive Psychology*, 1997. **6**(2): p. 69-79.
41. Bingel, U., *Placebo 2.0: the impact of expectations on analgesic treatment outcome*. *Pain*, 2020. **161**: p. S48-S56.
42. Rief, W., et al., *Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients: results of the randomized controlled PSY-HEART trial*. *BMC medicine*, 2017. **15**(1): p. 1-13.
43. Constantino, M.J., R.M. Ametrano, and R.P. Greenberg, *Clinician interventions and participant characteristics that foster adaptive patient expectations for psychotherapy and psychotherapeutic change*. *Psychotherapy*, 2012. **49**(4): p. 557.
44. Vîslă, A., M.J. Constantino, and C. Flückiger, *Predictors of change in patient treatment outcome expectation during cognitive-behavioral psychotherapy for generalized anxiety disorder*. *Psychotherapy*, 2021. **58**(2): p. 219.
45. Greenberg, R.P., M.J. Constantino, and N. Bruce, *Are patient expectations still relevant for psychotherapy process and outcome?* *Clinical psychology review*, 2006. **26**(6): p. 657-678.
46. Constantino, M.J., et al., *A meta-analysis of the association between patients' early treatment outcome expectation and their posttreatment outcomes*. *Psychotherapy*, 2018. **55**(4): p. 473.
47. Barber, J.P., et al., *The associations among improvement and alliance expectations, alliance during treatment, and treatment outcome for major depressive disorder*. *Psychotherapy Research*, 2014. **24**(3): p. 257-268.
48. Patterson, C.L., B. Uhlin, and T. Anderson, *Clients' pretreatment counseling expectations as predictors of the working alliance*. *Journal of Counseling Psychology*, 2008. **55**(4): p. 528.
49. Gollwitzer, M., A. Thorwart, and K. Meissner, *Editorial: Psychological Responses to Violations of Expectations*. *Frontiers in Psychology*, 2018. **8**: p. 3.
50. Rief, W. and J. Joormann, *Revisiting the cognitive model of depression: The role of expectations*. *Clinical Psychology in Europe*, 2019. **1**: p. 1-19.
51. Panitz, C., et al., *A revised framework for the investigation of expectation update versus maintenance in the context of expectation violations: the ViolEx 2.0 model*. *Frontiers in Psychology*, 2021: p. 5237.
52. Pinquart, M., et al., *Why expectations do or do not change after expectation violation: A comparison of seven models*. *Consciousness and Cognition*, 2021. **89**: p. 103086.
53. Rief, W., et al., *Using expectation violation models to improve the outcome of psychological treatments*. *Clinical Psychology Review*, 2022: p. 102212.
54. Craske, M.G., R.M. Rapee, and D.H. Barlow, *THE SIGNIFICANCE OF PANIC-EXPECTANCY FOR INDIVIDUAL PATTERNS OF AVOIDANCE*. *Behavior Therapy*, 1988. **19**(4): p. 577-592.
55. Craske, M.G., et al., *Maximizing exposure therapy: An inhibitory learning approach*. *Behaviour Research and Therapy*, 2014. **58**: p. 10-23.
56. Longmore, R.J. and M. Worrell, *Do we need to challenge thoughts in cognitive behavior therapy?* *Clinical psychology review*, 2007. **27**(2): p. 173-187.



- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
57. McManus, F., K. Van Doorn, and J. Yiend, *Examining the effects of thought records and behavioral experiments in instigating belief change*. Journal of behavior therapy and experimental psychiatry, 2012. **43**(1): p. 540-547.
58. Kube, T., et al., *Why dysfunctional expectations in depression persist - Results from two experimental studies investigating cognitive immunization*. Psychological Medicine, 2019. **49**(9): p. 1532-1544.
59. Kube, T., W. Rief, and J.A. Glombiewski, *On the Maintenance of Expectations in Major Depression - Investigating a Neglected Phenomenon*. Frontiers in Psychology, 2017. **8**.
60. Kube, T., et al., *How to modify persisting negative expectations in major depression? An experimental study comparing three strategies to inhibit cognitive immunization against novel positive experiences*. Journal of Affective Disorders, 2019. **250**: p. 231-240.
61. Kube, T., et al., *Focusing on situation-specific expectations in major depression as basis for behavioural experiments - Development of the Depressive Expectations Scale*. Psychology and Psychotherapy-Theory Research and Practice, 2017. **90**(3): p. 336-352.
62. Abramson, L.Y., M.E. Seligman, and J.D. Teasdale, *Learned helplessness in humans: critique and reformulation*. Journal of abnormal psychology, 1978. **87**(1): p. 49.
63. Liknaitzky, P., L.D. Smillie, and N.B. Allen, *Out-of-the-Blue: Depressive Symptoms are Associated with Deficits in Processing Inferential Expectancy-Violations Using a Novel Cognitive Rigidity Task*. Cognitive Therapy and Research, 2017. **41**(5): p. 757-776.
64. Kube, T., J.A. Glombiewski, and W. Rief, *Expectation-Focused Psychotherapeutic Interventions for People with Depressive Symptoms*. Verhaltenstherapie, 2019. **29**(4): p. 281-291.
65. Rief, W. and J.A. Glombiewski, *Expectation-Focused Psychological Interventions (EFPI)*. Verhaltenstherapie, 2016. **26**(1): p. 47-54.
66. Kolb, D.A., R.E. Boyatzis, and C. Mainemelis, *Experiential learning theory: Previous research and new directions*, in *Perspectives on thinking, learning, and cognitive styles*. 2014, Routledge. p. 227-248.
67. Kirchner, L., et al., *How social rejection expectations and depressive symptoms bi-directionally predict each other—A cross-lagged panel analysis*. Psychology and Psychotherapy: Theory, Research and Practice, 2022.
68. Rief, W. and J.A. Glombiewski, *The role of expectations in mental disorders and their treatment*. World Psychiatry, 2017. **16**(2): p. 210.
69. Külz, A.K., *Functional Analysis in Behaviour Therapy*. Verhaltenstherapie, 2014. **24**: p. 211-220.
70. Wittchen, H.U., et al., *SKID. Strukturiertes klinisches Inter-view für DSM-IV, Achse I, deutsche Version 1997*, Göttingen: Hogrefe.
71. Hautzinger, M., F. Keller, and C. Kühner, *BDI II. Beck-Depressions-Inventar*. Vol. 2. Auflage. 2009, London: Pearson.
72. Schmidtke, A., et al., *Studies of the reliability and validity of the German version of the Montgomery-Asberg Depression Rating Scale (MADRS)*. Schweizer Archiv für Neurologie und Psychiatrie (Zurich, Switzerland: 1985), 1988. **139**(2): p. 51-65.
73. Leiner, D.J., *SoSci Survey (Version 3.1.06) [Computer software]*. 2019.
74. Stenzel, N.M., T. Fehlinger, and A. Radkovsky, *Fertigkeitstrainings in der Verhaltenstherapie*. Verhaltenstherapie, 2015. **25**(1): p. 54-66.
75. Stenzel, N., et al., *Psychiatric comorbidity is associated with increased skill deficits*. Clinical psychology & psychotherapy, 2013. **20**(6): p. 501-512.

- 1  
2  
3 76. Fehlinger, T., et al., *Emotion regulation is the essential skill for improving depressive symptoms*. Journal of affective disorders, 2013. **144**(1-2): p. 116-122.
- 4  
5 77. Hautzinger, M., *Kognitive Verhaltenstherapie bei Depressionen*. 2013, Weinheim: Beltz Verlag.
- 6  
7 78. Faßbinder, E., et al., *Therapie-Tools Depression: Mit E-Book inside und Arbeitsmaterial*. 2015: Beltz.
- 8  
9 79. Schaub, A., E. Roth, and U. Goldmann, *Kognitiv-psychoedukative therapie zur bewältigung von depressionen: Ein therapiemanual*. Vol. 39. 2013: Hogrefe Verlag.
- 10  
11 80. Schmitz, N., et al., *The symptom check-list-90-R (SCL-90-R): a German validation study*. Quality of Life Research, 2000. **9**(2): p. 185-193.
- 12  
13 81. Bassler, M., B. Potratz, and H. Krauthauser, *Der "Helping Alliance Questionnaire" (HAQ) von Luborsky*. Psychotherapeut, 1995. **40**: p. 23-32.
- 14  
15 82. Devilly, G.J. and T.D. Borkovec, *Psychometric properties of the credibility/expectancy questionnaire*. Journal of Behavior Therapy and Experimental Psychiatry, 2000. **31**(2): p. 73-86.
- 16  
17 83. Gräfe, K., et al., *Screening psychischer Störungen mit dem "Gesundheitsfragebogen für Patienten (PHQ-D)"*. Diagnostica, 2004. **50**(4): p. 171-181.
- 18  
19 84. Krueger, C. and L. Tian, *A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points*. Biological research for nursing, 2004. **6**(2): p. 151-157.
- 20  
21 85. Kessler, R.C., et al., *Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication*. Archives of general psychiatry, 2005. **62**(6): p. 617-627.
- 22  
23 86. Goldberg, D. and J. Fawcett, *The importance of anxiety in both major depression and bipolar disorder*. Depression and anxiety, 2012. **29**(6): p. 471-478.
- 24  
25 87. Norcross, J.C. and B.E. Wampold, *What works for whom: Tailoring psychotherapy to the person*. Journal of clinical psychology, 2011. **67**(2): p. 127-132.
- 26  
27 88. Bundespsychotherapeutenkammer, B. *Ein Jahr nach der Reform der Psychotherapie-Richtlinie – Wartezeiten 2018*. 2018; Available from: [https://www.bptk.de/wp-content/uploads/2019/01/20180411\\_bptk\\_studie\\_wartezeiten\\_2018.pdf](https://www.bptk.de/wp-content/uploads/2019/01/20180411_bptk_studie_wartezeiten_2018.pdf).
- 28  
29 89. Brakemeier, E.-L., et al., *Die COVID-19-Pandemie als Herausforderung für die psychische Gesundheit*. Zeitschrift für Klinische Psychologie und Psychotherapie, 2020.
- 30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## 47 Figures

### 48 Figure 1. *Study Procedure*.

49  
50  
51 *Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic intervention

### 52 53 54 Figure 2. *Study Design*

55  
56  
57 *Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic treatment, T measurement timepoint, FU Follow-up


58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46


For peer review only

Figure 1. *Study Procedure.*



*Note.* Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic intervention

Figure 2. Study Design



Note. Abbreviations: TAU treatment as usual, CBT cognitive behavioral therapy, EFPI expectation focused psychotherapeutic treatment, T measurement timepoint, FU Follow-up

## Appendix

### A 1.

Study information and informed consent (Original in German)

## „Expectation Focused and Frequency Enhanced Cognitive-behavioral Therapy (EFFECT)“

### Informationsschreiben für Studienteilnehmerinnen und Studienteilnehmer

Liebe Studieninteressierte, Lieber Studieninteressierter,

wir freuen uns über Ihr Interesse an unserem Forschungsprojekt EFFECT, in dem wir einerseits kognitiv-verhaltenstherapeutische Behandlungen mit einmal wöchentlichen und zweimal wöchentlichen Therapiesitzungen vergleichen wollen und andererseits die Wirksamkeit von zwei kognitiv-verhaltenstherapeutischen Behandlungsmethoden vergleichen.

Das Therapieangebot ist Mittelpunkt eines Forschungsprojekts (Leitung: Prof. Dr. Winfried Rief, Professur für klinische Psychologie und Psychotherapie, Philipps-Universität Marburg).

### Worum geht es in dieser Studie?

Wir wissen aus verschiedenen Studien, dass Psychotherapie bei psychischen Erkrankungen wie Depressionen wirksam ist und zu einer Reduktion der depressiven Symptome führt. Wir wissen aber auch, dass es viele Faktoren gibt, die einen Einfluss auf den Erfolg der Behandlung haben können. Dazu gehört einerseits die Anzahl der Therapie-Sitzungen pro Woche. In dieser Studie wollen wir untersuchen, ob die Anzahl der Therapie-Sitzungen pro Woche (1 vs. 2) die Wirksamkeit der kognitiven Verhaltenstherapie zur Behandlung von Depressionen verbessern kann.

Weiterhin wissen wir aus der Forschung, dass Erwartungen unser Verhalten und unser Befinden beeinflussen können und sogar einen Einfluss auf den Therapie-Erfolg haben können. Deswegen geht es in dieser Studie auch darum neue und innovative erwartungsfokussierte Therapietechniken im Rahmen einer kognitiven Verhaltenstherapie zu untersuchen.

### Was ist kognitive Verhaltenstherapie (KVT) genau?

Die kognitive Verhaltenstherapie ist eine Form der Psychotherapie, welche sich vorrangig auf das Hier und Jetzt bezieht. Weiter geht die KVT davon aus, dass das Verhalten, die Gedanken und die Gefühle eng zusammenhängen, wobei die aktive Veränderung des Verhaltens und den Gedanken, die Gefühle dauerhaft verändern kann. Das Verhalten das ein Mensch zeigt, ist meist ein Ergebnis von bewussten und nichtbewussten Lernprozessen. Im Rahmen der Psychotherapie wird das Verhalten gemeinsam analysiert, um es später bewusst zu ändern. Kognitionen beziehen sich auf unser Denken. Dabei wird geschaut, welche Gedanken zur psychischen Störung beitragen, um diese mit verschiedenen Techniken zu ändern oder zu ersetzen. Weiter werden eigene Stärken und Fähigkeiten benutzt, um diesen Veränderungsprozess zu unterstützen.

### Was ist der Nutzen?

Mit Ihrer Teilnahme leisten Sie einen wichtigen Beitrag für die Wissenschaft und erlauben uns einerseits depressive Störungen und andererseits die Wirkungsweisen von psychotherapeutischen Behandlungen

besser zu verstehen, um weiterhin die Behandlungsmöglichkeiten stetig anpassen und verbessern zu können.

### **Wer kann an dieser Studie teilnehmen?**

Alle Personen über 18 Jahren können sich für die Studie anmelden. Gute Deutschkenntnisse werden vorausgesetzt. Nach der Durchführung eines Interviews und dem Ausfüllen der Fragebögen wird überprüft, ob alle Kriterien für den Einschluss in die Studie erfüllt sind. Dies wird mit Ihnen in einem Rückmeldegespräch besprochen und das weitere Vorgehen wird geplant. In diesem Gespräch werden Sie dann auch Rückmeldung über die Diagnostik bekommen.

### **Wie sieht der Ablauf der Studie aus?**

Nach dem ersten Anmeldegespräch in der Ambulanz und nach Ihrer Entscheidung, an der Studie teilnehmen zu wollen, werden Sie zufällig einer von drei Behandlungsbedingungen und einem/einer Therapeuten/Therapeutin zugeteilt. Danach folgen 7 Sitzungen, welche zur ausführlichen Diagnostik dienen (je nach Bedingung zweimal wöchentlich oder einmal wöchentlich). In diesen 7 Sitzungen wird der/die Therapeut/ Therapeutin mithilfe von Fragebögen und Interviews eine Diagnose nach den Kriterien der internationalen Diagnostiksysteme (ICD-10 und DSM-IV) stellen und einen Antrag an die Krankenkasse für die Kostenübernahme der Psychotherapie stellen.

Nach diesen 7 Sitzungen beginnt die Behandlung. Diese beträgt dann 24 Therapie-Sitzungen. Je nach Zufallszuteilung werden die Sitzungen zweimal pro Woche oder einmal pro Woche stattfinden. Damit wir die Erfolge der Therapie beurteilen können, werden Sie verschiedene Fragebögen zu verschiedenen Zeitpunkten ausfüllen. Diese Fragebögen beziehen sich vor allem auf Ihre aktuellen Belastungen, Ihre Stimmung, Ihre Erwartungen und Ihre subjektive Beurteilung des Therapie-Erfolges und der Beziehung zum/zur Therapeuten/ Therapeutin. Die Messzeitpunkte, bei denen Sie diese Fragebögen ausfüllen, werden einmal am Anfang der Therapie, einmal in der 10. Therapiewoche, nach der 20., nach der 24. Therapiewoche und nach 3 Monaten nach dem Therapie-Ende, sowie nach 2 Jahren stattfinden.

### **Wie wird man der Art und Form der Behandlung zugeordnet?**

Die Therapieformen (KVT und KVT mit erwartungsfokussierten Interventionen (EFPI); Sitzungen 1 vs. 2 mal pro Woche) entsprechen dem neuesten Stand der Wissenschaft. Alle Behandlungen werden von speziell ausgebildeten Therapeutinnen und Therapeuten durchgeführt. Die Zuordnung zu einer Bedingung erfolgt per Zufall, d.h. jeder Teilnehmer/ jede Teilnehmerin wird per Zufallsentscheidung und nicht aufgrund bestimmter Eigenschaften einer der drei Therapieformen zugeordnet.

### **Was sind mögliche Nebenwirkungen, Belastungen und Risiken?**

Bislang gibt es aus der Forschung nur sehr wenige Belege für Nebenwirkungen in der Psychotherapie. In der geplanten Studie sind keine negativen Effekte auf Sie zu erwarten. Die Therapie an sich kann anstrengend und ermüdend sein und kann manchmal negative Gefühle auslösen. Um diese negativen Effekte kontinuierlich erfassen zu können, wird der Therapeut/ die Therapeutin Sie in jeder Stunde nach Ihrem aktuellen Befinden fragen, um mögliche negative Gefühle aufgreifen und bearbeiten zu können. Alle Therapeutinnen und Therapeuten stehen unter Supervision (Aufsicht) von ausgebildeten und sehr erfahrenen Psychotherapeutinnen. Falls die Behandlung nicht zum gewünschten Erfolg führt, können optionale Behandlungsmöglichkeiten mit der Psychotherapeutin/ dem Psychotherapeuten diskutiert werden.

### **Abbruch und Widerrufsrecht**

1  
2  
3 Die Teilnahme an der Studie ist freiwillig. Sie können jederzeit und ohne Angabe eines Grundes Ihre  
4 Einverständniserklärung zurückziehen und aus der Studie aussteigen. Der Rücktritt ist mit keinerlei  
5 Kosten oder Nachteilen verbunden. Es wird weiterhin die Möglichkeit geben, eine ambulante Therapie  
6  
7 an der Hochschulambulanz zu machen. Auf Wunsch können außerdem alle Daten, die im Rahmen der  
8 Studie erhoben wurden, gelöscht werden.  
9

## 10 **Datenschutz**

11  
12  
13 **Personenbezogene Daten während Therapie-Durchlauf:** Die Therapeutinnen und  
14 Therapeuten sind verpflichtet alle personenbezogenen Dokumentationen in einer Therapie-  
15 Akte in abschließbaren Schränken aufzubewahren. Für die Sicherstellung der Qualität der  
16 Behandlung sind u. U. Video-Aufnahmen von Therapiesitzungen notwendig, welche auf einer  
17 passwortgeschützten Festplatte in abgeschlossenen Schränken aufbewahrt werden. Diese  
18 Videos werden nach Abschluss der Studie und nach der Beurteilung der Therapie-  
19 Durchführung zur Qualitätssicherung während der Therapie gelöscht. Therapie-Akten werden  
20 nach Therapie-Ende gemäß den Aufbewahrungsfristen der DSGVO 10 Jahre aufbewahrt.  
21  
22

23 **Kodierliste:** Die Erhebung, Speicherung und Verarbeitung der persönlichen Daten (demographische  
24 Daten wie Alter und Geschlecht, Ergebnisse der Fragebögen und Interviews) erfolgen  
25 pseudonomisiert unter Verwendung eines Codes, ohne Angaben ihres Namens. Es existiert eine  
26 Kodierliste auf Papier (im Institut Psychologie, AG klinische Psychologie und Psychotherapie  
27 Philipps-Universität Marburg), welche Ihren Namen mit Ihrem zugeordneten Code verbindet. Diese  
28 Liste ist nur den V ersuchsleiter/innen (Studientherapeutinnen und Studientherapeuten) und dem  
29 Projektleiter zugänglich. Diese Liste wird in einem verschließbaren Schrank aufbewahrt und nach  
30 Abschluss der Studie vernichtet. Ihre Daten sind ab dem Zeitpunkt komplett anonymisiert. Es ist dann  
31 nicht mehr möglich, den Code Ihrem Namen zuzuordnen. Solange diese Liste existiert, können Sie  
32 jederzeit die Löschung Ihrer Daten beantragen. Ab der Löschung der Liste ist dies nicht mehr möglich.  
33  
34

35 **Studien- und Datenqualität:** Zur Qualitätssicherung der Durchführung der Studie werden Studien-  
36 unabhängige Prüferinnen und Prüfer, vorausgesetzt Ihrer schriftlichen Einverständniserklärung zur  
37 Schweigepflichtsentbindung, Einblick in personenbezogene Daten (v.a. Therapie-Sitzungen) nehmen,  
38 um die Durchführung der Therapie zu überprüfen. Weiterhin können mit Ihrer Unterschrift zur  
39 Schweigepflichtsentbindung Supervisorinnen und Supervisoren Einblick in personenbezogene Daten  
40 nehmen (Videos, Akten), um die Studientherapeutinnen und Studientherapeuten bestmöglichst bei der  
41 Therapie-Durchführung zu unterstützen.  
42  
43

44 Diese Befragung wird mit Hilfe des Portals <https://www.sosicisurvey.de> durchgeführt. Hierbei werden  
45 folgende zentrale Sicherheitsaspekte berücksichtigt: keine Speicherung der IP-Adressen in den  
46 Logfiles, es findet eine SSL-Verschlüsselung statt und der Server befindet sich in München,  
47 Deutschland. Die detaillierten Hinweise zum Datenschutz können unter folgendem Link nachgelesen  
48 werden: <https://www.sosicisurvey.de/index.php?page=privacy>.  
49

## 50 **Ansprechpartner**

51  
52 Diese Studie wird unter Leitung von Herrn Prof. Dr. Winfried Rief, Arbeitsgruppe Klinische  
53 Psychologie und Psychotherapie, Fachbereich Psychologie der Philipps-Universität Marburg,  
54 Gutenbergstraße 18, 35037 Marburg durchgeführt.  
55

56 Ansprechpartner für die Studie sind:

- 57  
58  
59 • Frau M. Sc. Anne-Catherine Ewen (Telefon: 06421 28 24053, E-Mail: [ewen@staff.uni-](mailto:ewen@staff.uni-marburg.de)  
60 [marburg.de](mailto:ewen@staff.uni-marburg.de))

- Herr Dr. Marcel Wilhelm (Telefon: 06421 28 23617, E-Mail: [marcel.wilhelm@staff.uni-marburg.de](mailto:marcel.wilhelm@staff.uni-marburg.de))
- Frau Dr. Pia von Blanckenburg (Telefon: 06421 28 2405, E-Mail: [blanckep@staff.uni-marburg.de](mailto:blanckep@staff.uni-marburg.de))
- Frau Dr. Gaby Bleichhardt (Telefon: 06421 28 2369, E-Mail: [gaby.bleichhardt@staff.uni-marburg.de](mailto:gaby.bleichhardt@staff.uni-marburg.de))
- Frau Dr. Katrin Wambach (Telefon: 06421 28 23681, E-Mail: [wambach@staff.uni-marburg.de](mailto:wambach@staff.uni-marburg.de)) Der verantwortliche Studienleiter,  
Herr Prof. Dr. Winfried Rief (Telefon: 06421 28 23641, E-Mail: [riefw@staff.uni-marburg.de](mailto:riefw@staff.uni-marburg.de)),  
kann ebenfalls bei weiteren Fragen kontaktiert werden.

Wenn Sie alle Informationen gelesen und verstanden haben, die Gelegenheit für Rückfragen hatten und diese angemessen beantwortet wurden, bitten wir Sie Ihre Teilnahme an der Studie mit der Unterschrift auf der beiliegenden Einverständniserklärung zu bestätigen.

Herzlichen Dank!

**Ihr EFFECT-Studien-Team**

**E-Mail:** effect04@uni-marburg.de **Tel:**06421-22834

## Einverständniserklärung zur Studienteilnahme

Mir wurde von Frau/ Herrn \_\_\_\_\_ ausführlich erklärt, worum es in der EFFECT-Studie geht.

Ich, \_\_\_\_\_ (Name der Teilnehmerin / des Teilnehmers), habe ein Informationsblatt mit näheren Informationen zum Ziel und Ablauf der oben genannten Studie erhalten („Studieninformation“). Ich habe alle Informationen vollständig gelesen und verstanden. Sofern ich Fragen zu der Studie hatte, wurden sie vollständig und zu meiner Zufriedenheit beantwortet.

Ich erkläre mich mit den im Informationsblatt („Studieninformation für Teilnehmerinnen und Teilnehmer“) beschriebenen Erklärungen und Studienbedingungen und mit der beschriebenen Handhabung der erhobenen Daten einverstanden. Ich wurde darüber informiert, dass meine Teilnahme freiwillig ist. Ich weiß, dass ich jederzeit und ohne Angabe von Gründen meine Zustimmung zur Teilnahme widerrufen kann, ohne dass mir dadurch irgendwelche Nachteile entstehen. Wenn die Notwendigkeit besteht, kann ich weiter an einer ambulanten Psychotherapie an der Psychotherapie-Ambulanz Marburg/ Institut für Psychotherapie-Ausbildung Marburg (PAM/ IPAM) teilnehmen. Mir ist bekannt, wie und von wem meine persönlichen Daten im Rahmen der Studie verarbeitet werden. Wenn ich das möchte, weiß ich, dass ich die Löschung meiner Daten einfordern kann.

Eine Ausfertigung der Teilnehmerinformationen und Einwilligungserklärung habe ich erhalten. Ich hatte genügend Zeit eine Entscheidung zu treffen und erkläre mich hiermit bereit, an der oben genannten Studie teilzunehmen.

\_\_\_\_\_ Name des Teilnehmers/ der Teilnehmerin

\_\_\_\_\_ Name des Diagnostikers/ der Diagnostikerin

\_\_\_\_\_ Ort, Datum und Unterschrift des Teilnehmers/ der Teilnehmerin

\_\_\_\_\_ Ort, Datum und Unterschrift des Diagnostikers/ der Diagnostikerin

## A 2. Content examples of the CBT- versus the EFPI-manual.

<b>CBT-modules</b>		
Psychoeducation depression	First session	Introduction of cognitive-behavioral therapy explanatory models and development of an individual disorder model
Depending on the main problems, selection of modules for six therapy sessions	Daily problems	Promote problem solving skills, work on current problems
	Emotion regulation	Functionality of emotions, emotions and needs, mindfulness/ acceptance for emotions, emotion analysis
	Relaxation	Psychoeducation stress vs. relaxation, Progressive muscle relaxation
	Inactivity	Depression spiral, week protocols, positive activities
	Self-esteem	Am-me, should-me, wish-me, dysfunctional self-devaluation, sources of self-esteem
	Social competences	Elaborating interpersonal problems, role plays
	Cognitions	Cognitive triad, ABC(DE)-scheme, work on dysfunctional thoughts
Individual buffer	Four sessions	Depending on the needs of the client
End	24 <sup>th</sup> session	relapse prevention and conclusion
<b>EFPI-modules</b>		
Psychoeducation of depression in consideration of expectation processes	Five therapy sessions	Introduction to „unhelpful (dysfunctional)“ expectations integrated in cognitive-behavioral explanation models, expectation persistence mechanisms based on the ViolEx-model, behavioral experiments
Flexible application of different topics with the aim of planning one behavioral experiment per therapy session to test own expectations (examples based on the CBT modules)	Social competences	e.g., as part of a behavioral experiment, try out a new social skill at home and evaluate it
	Relaxation	e.g., In the context of a behavioral experiment, taking time for oneself, PMR, mindfulness practice and evaluate it
	Inactivity	e.g., In the context of a behavioral experiment, trying a new activity and evaluate it
	Self-esteem	e.g., In the context of a behavioral experiment, try changed expectations to oneself, formulating positive things about oneself and evaluate it
	Emotion regulation	e.g., In the context of a behavioral experiment, trying a certain emotion regulation strategy and evaluate it
	Daily problems	e.g., In the context of a behavioral experiment, test certain solutions and evaluate it
	Cognitions (expectations)	e.g., In the context of a behavioral experiment, try other thoughts/ expectations and evaluate it
End	Last session	relapse prevention and conclusion



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	YES
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	YES
	2b	All items from the World Health Organization Trial Registration Data Set	YES
Protocol version	3	Date and version identifier	YES
Funding	4	Sources and types of financial, material, and other support	
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	/
	5b	Name and contact information for the trial sponsor	/
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	/(no funder)
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	/
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	YES
	6b	Explanation for choice of comparators	YES
Objectives	7	Specific objectives or hypotheses	YES
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	YES

---

**Methods: Participants, interventions, and outcomes**


---

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	YES
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	YES
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	YES
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	YES
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	YES
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	YES
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	YES
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	YES
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	YES
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	YES

---

**Methods: Assignment of interventions (for controlled trials)**


---

Allocation:

---

1				
2	Sequence	16a	Method of generating the allocation sequence (eg, computer-	YES
3	generation		generated random numbers), and list of any factors for stratification.	
4			To reduce predictability of a random sequence, details of any planned	
5			restriction (eg, blocking) should be provided in a separate document	
6			that is unavailable to those who enrol participants or assign	
7			interventions	
8				
9				
10	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central	YES
11	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
12	mechanism		describing any steps to conceal the sequence until interventions are	
13			assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,	YES
16			and who will assign participants to interventions	
17				
18	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial	YES
19	(masking)		participants, care providers, outcome assessors, data analysts), and	
20			how	
21				
22				
23		17b	If blinded, circumstances under which unblinding is permissible, and	YES
24			procedure for revealing a participant's allocated intervention during	
25			the trial	
26				
27				
28	<b>Methods: Data collection, management, and analysis</b>			
29				
30	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other	YES
31	methods		trial data, including any related processes to promote data quality (eg,	
32			duplicate measurements, training of assessors) and a description of	
33			study instruments (eg, questionnaires, laboratory tests) along with	
34			their reliability and validity, if known. Reference to where data	
35			collection forms can be found, if not in the protocol	
36				
37				
38		18b	Plans to promote participant retention and complete follow-up,	YES
39			including list of any outcome data to be collected for participants who	
40			discontinue or deviate from intervention protocols	
41				
42	Data	19	Plans for data entry, coding, security, and storage, including any	YES
43	management		related processes to promote data quality (eg, double data entry;	
44			range checks for data values). Reference to where details of data	
45			management procedures can be found, if not in the protocol	
46				
47				
48	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.	YES
49	methods		Reference to where other details of the statistical analysis plan can be	
50			found, if not in the protocol	
51				
52		20b	Methods for any additional analyses (eg, subgroup and adjusted	YES
53			analyses)	
54				
55		20c	Definition of analysis population relating to protocol non-adherence	YES
56			(eg, as randomised analysis), and any statistical methods to handle	
57			missing data (eg, multiple imputation)	
58				
59				
60	<b>Methods: Monitoring</b>			

1				
2	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	/
3				
4				
5				
6				
7				
8				
9		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	YES
10				
11				
12				
13	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	YES
14				
15				
16				
17	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	YES
18				
19				
20				
21				
22	<b>Ethics and dissemination</b>			
23	<hr/>			
24				
25				
26				
27	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	YES
28				
29				
30	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	YES
31				
32				
33				
34				
35				
36	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	YES
37				
38				
39				
40		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	/
41				
42	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	YES
43				
44				
45				
46				
47	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	/
48				
49				
50	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	YES
51				
52				
53				
54	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	/
55				
56				
57				
58				
59				
60				

1				
2	Dissemination	31a	Plans for investigators and sponsor to communicate trial results to	
3	policy		participants, healthcare professionals, the public, and other relevant	
4			groups (eg, via publication, reporting in results databases, or other	
5			data sharing arrangements), including any publication restrictions	
6				
7		31b	Authorship eligibility guidelines and any intended use of professional	YES
8			writers	
9				
10		31c	Plans, if any, for granting public access to the full protocol, participant-	/(In
11			level dataset, and statistical code	Prere
12				gistra
13				tion)
14				
15				
16	<b>Appendices</b>			
17				
18	Informed consent	32	Model consent form and other related documentation given to	YES
19	materials		participants and authorised surrogates	
20				
21	Biological	33	Plans for collection, laboratory evaluation, and storage of biological	/
22	specimens		specimens for genetic or molecular analysis in the current trial and for	
23			future use in ancillary studies, if applicable	
24				

25

26

27

28 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013

29 Explanation & Elaboration for important clarification on the items. Amendments to the

30 protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT

31 Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)"

32 license.

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60